<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:georss='http://www.georss.org/georss' xmlns:gd='http://schemas.google.com/g/2005' xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-8882220068057629879</id><updated>2011-11-27T16:06:53.701-08:00</updated><title type='text'>Low Dose Naltrexone (LDN) on the NHS LDN on the NHS</title><subtitle type='html'>Low Dose Naltrexone is simply a much smaller dosage (Typically 1/50) of a 30 year old proven drug called Naltrexone. LDN has increasingly been shown to put a wide variety of auto-immune and other conditions (e.g. Crohn's Disease, Multiple Sclerosis (MS) into remission with virtually no side effects.</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default?max-results=100'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>83</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>100</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3782980456286863468</id><published>2011-03-19T07:38:00.000-07:00</published><updated>2011-03-19T07:39:49.663-07:00</updated><title type='text'>Excellent Presentation on LDN and 'Toll Like' Receptors (TLR2 etc)</title><content type='html'>&lt;div&gt;Dr Rachel Allen at the Birmingham LDN Conference 2010 -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;Part 1: &lt;a href="http://www.youtube.com/watch?v=9zV7XeN0yes"&gt;http://www.youtube.com/watch?v=9zV7XeN0yes&lt;/a&gt;&lt;/div&gt;&lt;div&gt;Part 2: &lt;a href="http://www.youtube.com/watch?v=JKG8MQdHnh0"&gt;http://www.youtube.com/watch?v=JKG8MQdHnh0&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3782980456286863468?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3782980456286863468/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2011/03/excellent-presentation-on-ldn-and-toll.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3782980456286863468'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3782980456286863468'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2011/03/excellent-presentation-on-ldn-and-toll.html' title='Excellent Presentation on LDN and &apos;Toll Like&apos; Receptors (TLR2 etc)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8001962821276032292</id><published>2010-05-13T06:53:00.001-07:00</published><updated>2010-05-13T06:53:13.942-07:00</updated><title type='text'>Revolution Health Users Give Top Marks to Low Dose Naltrexone (LDN) for Crohn's Disease</title><content type='html'>&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande', sans-serif; font-size: 14px; color: rgb(61, 25, 87); line-height: 16px; "&gt;&lt;a href="http://www.revolutionhealth.com/drugs-treatments/rating/naltrexone-for-crohns-disease"&gt;http://www.revolutionhealth.com/drugs-treatments/rating/naltrexone-for-crohns-disease&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8001962821276032292?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8001962821276032292/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/05/revolution-health-users-give-top-marks.html#comment-form' title='32 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8001962821276032292'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8001962821276032292'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/05/revolution-health-users-give-top-marks.html' title='Revolution Health Users Give Top Marks to Low Dose Naltrexone (LDN) for Crohn&apos;s Disease'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>32</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3276601880161220610</id><published>2010-05-13T06:45:00.000-07:00</published><updated>2010-05-13T06:48:08.121-07:00</updated><title type='text'>Abstract of Phase II Trial Results for Low Dose Naltrexone (LDN) for Crohn's Disease from Dr Jill Smith, Penn State University</title><content type='html'>&lt;a href="http://bit.ly/d6SZo3"&gt;Abstract Link&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;div&gt;This is a highly significant result for Low Dose Naltrexone as it's a Phase II study which was carried out under randomised, double-blind, placebo-controlled conditions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;Summary -&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;45% of 40 patients achieved remission inside 12 weeks.&lt;/div&gt;&lt;div&gt;(Note, clinical experience shows it can take more than 3 months to really get results with LDN and certainly 4.5mg is often too high a dose too).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;82% of the 40 patients had their Crohn's improve by around 20% or more in terms of its activity.&lt;br /&gt;Healing was reported in the endoscopy studies too.&lt;br /&gt;&lt;br /&gt;Although this is not quite as impressive a result as the first study, it is at least as good as many other treatments and with a lot, lot less side effects (Only reversible liver enzyme changes reported).&lt;br /&gt;&lt;br /&gt;For comparison, this anti-TNF treatment managed 40% remission after 5 years, chances are LDN could be 5%+ better than that :&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;a href="http://www.medpagetoday.com/MeetingCoverage/DDW/19885"&gt;http://www.medpagetoday.com/MeetingCoverage/DDW/19885&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Remicade + azathioprine managed roughly 50% remission after 26 weeks, but that is of course at a big price financially and in terms of side-effects - &lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;a href="http://www.webmd.com/ibd-crohns-disease/crohns-disease/news/20100414/combination-therapy-treats-crohns-disease"&gt;http://www.webmd.com/ibd-crohns-disease/crohns-disease/news/20100414/combination-therapy-treats-crohns-disease&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Obviously a Phase III study will be interesting now as it will have a much bigger patient population and maybe run longer too.&lt;br /&gt;Would be interesting to see how the remission rate is after another 3 months.&lt;br /&gt;Would be even more interesting to see how it was if the patients were allowed to decrease dose too.&lt;br /&gt;&lt;br /&gt;Note that Dr Smith has another study starting on Vitamin D with Crohn's too.&lt;/div&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3276601880161220610?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3276601880161220610/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/05/abstract-of-phase-ii-trial-results-for.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3276601880161220610'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3276601880161220610'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/05/abstract-of-phase-ii-trial-results-for.html' title='Abstract of Phase II Trial Results for Low Dose Naltrexone (LDN) for Crohn&apos;s Disease from Dr Jill Smith, Penn State University'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8270218232255901820</id><published>2010-04-27T01:32:00.001-07:00</published><updated>2010-04-27T01:32:42.001-07:00</updated><title type='text'>2nd European Low Dose Naltrexone Conference Summary</title><content type='html'>Below is a copy of the live tweeting LDN Now Scotland did from the 2nd European Low Dose Naltrexone Conference in Glasgow, Scotland on 24th April 2010.&lt;br /&gt;&lt;br /&gt;These were originally published via twitter at -&lt;br /&gt;&lt;br /&gt;http://twitter.com/LDNNow&lt;br /&gt;&lt;br /&gt;@tomgilhooly Opening the conferenceLDN Now "Troublemakers" "Agitators" ! hehe #bigonldn20102:18 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Importance of patient groups being talked about. #bigonldn2010#ldnnow2:19 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Dr Tom looking for a Glasgow based Neurologist in order to get funding for MS trial. #bigonldn20102:20 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Stephen Dickson of Dickson's Pharnacy up first on#lowdosenaltrexone dispensing. #bigonldn20102:21 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;2500+ #lowdosenaltrexone patients on Dickson's books200 Drs 2008 now 683 in A Dr Wright using it for varied conditions#bigonldn20102:24 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Stable #lowdosenaltrexone supply chain in UKDrug interactions and adverse reactions more common (Because of more use) Useful#bigonldn20192:25 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;More neurologists referring GP to prescribe #lowdosenaltrexone#bigonldn20102:26 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;More #lowdosenaltrexone / ALA for cancer treatment.#bigonldn2010 99 LDN phone calls on one Saturday.2:28 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Feedback on #lowdosenaltrexone very positive. #bigonldn20102:29 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Dickson's now supplying #lowdosenaltrexone cream for children.#bigonldn20102:31 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;No placebo response from Autistic kids on #lowdosenaltrexoneCompelling efficacy evidence. #bigonldn20102:32 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Type 1 diabetes and depression now being treated successfully with #lowdosenaltrexone #bigonldn20102:33 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;34 yr old ME patient1 month on 3mg #lowdosenaltrexone Good response.2:34 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Developed inflammatory response on #lowdosenaltrexone which went away when LDN stopped and returned on LDN #bigonldn20102:35 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Perhaps #lowdosenaltrexone triggered response to underlying infection not being fought without LDN #bigonldn20102:36 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Patient reported elimination of allergies and need for asthma inhaler on #lowdosenaltrexone #bigonldn20102:37 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Can still take many drugs with #lowdosenaltrexone e.gMesalazine , azathioprine (Stable dose), interferon and copaxone#bigonldn20102:39 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Anti-convulsants and epiliptic drugs generally ok with#lowdosenaltrexone too #bigonldn20102:40 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Inadvisable with #lowdosenaltrexone Roaccutane (No info available) , MST, SR Morphine, Fentanyl, Ketamine #bigonldn20102:42 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;#vitaminD a key additional treatment for MS (And others)2:54 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Study shows that Vitamin D dramatically reduces the production of inflammatory LT #bigonldn20102:56 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Likely that Vitamin D alone may slow down progression of #MS due to the suppression of the inflammatory response #bigonldn20102:58 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Gene expression affected by Vitamin D - less vitamin D -&gt; more likely to develop #MS #bigonldn2010 - Stephen Dickson2:59 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;'Resveratrol', being investigated as anti-ageing agentNeuro protective effects being reported on now. #bigonldn2010 #MS3:00 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#Resveratrol immunomodulates the immune response in a way which is neuro-protective for #MS #bigonldn20103:01 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#Resveratrol causes death of immune response cells, so potentially useful for treatment of autoimmune and inflammatory disease#bigonldn20103:02 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#reveratrol study going on now at University of MissouriInterim conclusion - useful for neurodegenerative diseases #bigonldn20103:04 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#resveratrol generally seems to reduce mortalityObese mice lived as long as healthy ones on this drug. #bigonldn20103:04 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#resveratrol 1000-1500mg per day dosage. #bigonldn20103:06 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Other useful supplements - Alpha-Lipoic Acid, L-carnitine, Beta-D- Glucan and chromium, Green Tea #bigonldn20103:08 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Pat Crowely now, on his experience with #lowdosenaltrexone in Ireland #bigonldn20103:38 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Over 30 deaths in the EU from Tysabri for #MS #bigonldn20103:41 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Example of the situation with #lowdosenaltrexone Triple therapy for gastric ulcers, ridiculed but ultimately Nobel prize #bigonldn20103:47 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;(Recommendation from @tomgilhooly on Vitamin D - Get your GP to test Vit D level in summer and winter &amp; take up to 4000IU/day#bigonldn2010)3:48 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;(Get your Vitamin D level up to 100) #bigonldn20103:49 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Low Omega 3 levels in MS patient a problem, also noticed patient with #MS and very high iron levels. #bigonldn20103:50 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone highly useful for middle aged #MS females with PPMS #bigonldn20103:50 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;(Quote from Machiavelli on the difficulty of usurping an existing system - e.gNon #lowdosenaltrexone therapies with LDN)#bigonldn20103:52 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dr Paulo Zamboni - Liberation treatment CCSVI #bigonldn20103:54 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#bigonldn2010 #lowdosenaltrexone EU ConfL-R Stephen Dickson, @tomgilhooly Dr Bob LawrencePat Crowely presentinghttp://yfrog.com/5xfubj3:55 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;[Talking about the efforts pharma companies make to play down CCSVI and LDN in favour of their products] #bigonldn20104:00 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Non of Dr Bihari's #MS work on #lowdosenaltrexone was allowed to be published.4:01 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;One medic who was pro #lowdosenaltrexone now describes it as useless (He is now a main player in Tysabri in Ireland,Go figure)#bigonldn20104:02 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;DrJeffrey Dach #lowdosenaltrexone 'greatest medical discovery of the [20th] century' #bigonldn20104:03 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone is a 'mass movement driven by people [not pharma]'4:03 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Pat unable to prescribe #lowdosenaltrexone for #crohns due to lack of co-operation by GI consultants who are resistant. #bigonldn20104:04 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#ldnnow comment - As ever, the picture is one where those who know about #lowdosenaltrexone and use it are positive.#bigonldn20104:05 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#ldnnow comment - Those who are ignorant of #lowdosenaltrexoneare skeptical but won't try it. #bigonldn20104:06 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Big problem is lack of knowledge of #lowdosenaltrexone in doctors.#bigonldn20104:08 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;10,000 #MS patients in Ireland and less than 40 neurologists - less than the Czech Republic #bigonldn20104:10 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Talking about @ldndatabase proposal for #lowdosenaltrexoneresearch in Ireland #bigonldn20104:11 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Vote now for @ldndatabase proposal for 500K GBP for#lowdosenaltrexone research - http://bit.ly/chjraq #bigonldn20104:12 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dr Pat Crowley presentation endsZoe Cameron, #crohn's patient on #lowdosenaltrexone speaking next. #bigonldn20104:15 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Zoe speaking of her diaries she kept throughout her experience of#crohn's disease and #lowdosenaltrexone #bigonldn20104:15 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#bigonldn2010 A #crohn's patient's experience on#lowdosenaltrexone http://yfrog.com/juo40zj4:16 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Zoe had food poisoning from undercooked chicken which did not improve which led to #crohn's diagnosis. #bigonldn20104:17 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Zoe improved on #prednisolone for #crohn's with side-effects, coming off steroids #crohn's returnedYo yo of steroids on/off#bigonldn20104:18 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Speaking of the sadness of the possible outcomes with #crohn's and the dark humour of patients #bigonldn20104:19 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Trying all sorts of diets and regimes, including no yeast, liquid only diet etcfor #crohn's #bigonldn20104:20 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Went from 10 1/2 stone (5 foot 8), down to 7 stone (BMI 14), hospitalisation mooted by DrsSerious conditon. #bigonldn20104:21 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Then terrified of eating with #crohn's Drs critisised Zoe for trying alternatives to immuno-suppresants #bigonldn20104:23 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Zoe's uncle, a US Dr suggested #lowdosenaltexone GP was intrigued and willing to try LDN on routine blood tests and weigh-ins#bigonldn20104:24 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Interrupted sleep side effect of #lowdosenaltrexone seemed minor compared to 10 crohn's trips to the toilet per night #bigonldn20104:25 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;By week 3 on #lowdosenaltrexone Zoe gained weightAfter a few months GP told her to 'avoid doctors'! Much better. #bigonldn20104:26 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;After a year,could eat salad &amp; popcornNow eats what she wants and only has symptoms when run down #lowdosenaltrexone#bigonldn2010 #crohns4:28 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q &amp; A Interferons and #lowdosenaltrexone ? Dr Bob Lawrence - Not compatible. #bigonldn20104:31 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone Q&amp;A before lunch. #bigonldn2010http://yfrog.com/2om71uj4:31 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Dr Pat Crowley - No interferons with #lowdosenaltrexone but safe to try it for a month and see. #bigonldn2010 Stephen Dickson agrees.4:31 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q - How do we know #lowdosenaltrexone doesn't just make the patient 'feel' better only due to endorphins? #bigonldn20104:32 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A - Zoe - With #crohn's gained weight on #lowdosenaltrexone and bad symptom days very few and far between #bigondldn20104:33 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A - @tomgilhooly google 'Dr Jill Smith Low Dose Naltrexone' Compelling results. #lowdosenaltrexone #bigonldn20104:34 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#ldnnow comment, Dr Jill Smith's double-blind, placebo-controlled, randomised trial for #crohn's and #lowdosenaltrexone in May#bigonldn20104:34 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#ldnnow comment - Dr Smith's study will be presented at a conference in May 2010 #crohn's #lowdosenaltrexone#bigonldn20104:36 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q - Prednisolone, restrict to 10mg or OK to go higher as Dr Zagon says is OK? #bigonldn2010 #lowdosenaltrexone4:41 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A - Dr Tom - Dr Ian Zagon most knowledgeable about#lowdosenaltrexone So no reason to disagree with him.#bigonldn20104:42 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q - Dr Ian Zagon, OK to take CRABB drugs with#lowdosenaltrexone #bigonldn20104:42 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A - Dr Tom - Need to remember though that Dr Zagon is a researcher rather than an medical doctor #bigonldn2010#lowdosenaltrexone4:43 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;RT @DiamonDie: Tom Gilhooly thinks Crohn's and CFS/ME are two conditions that respond the best to LDN: IMO it works better in MS than CF ...4:43 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;(i.eClinical experience can sometimes differ from research environment) #ldnnow comment - Difficult for patients to know what to do.4:45 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q - MS with seizures, taking #lowdosenaltrexone and anti-convulsants - can reduce anti-convulsants?4:47 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q - Concerned about anti-convulsants' long-term damage to liver.#bigonldn20104:48 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A - Work with a neurologist to see if can be reduced and still OK on#lowdosenaltrexone #bigonldn20104:49 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Average Vitamin D level in Scotland 30,40 aim for 10#bigonldn2010 Can be 250 or higher though.4:52 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Q - #lowdosenaltrexone effective at late stages of #MS?4:55 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A - Dr Bob Lawrence Yes but the earlier #MS treated with#lowdosenaltrexone the better as damage is not repaired generally.#bigonldn20104:55 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dr Jarred Younger's reseach on #lowdosenaltrexone for CFS/ME being unveiled at 2PM exclusively. #bigonldn20105:02 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Jarred Younger PhD, Rebecca McCue BS, Sean Mackey, MD, PhD - Fibromyalgia and Low Dose Naltrexone #bigonldn2010#lowdosenaltrexone6:11 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Preliminary results on #lowdosenaltrexone for #FM funded by Jim and Connie Binns and AFSA #bigonldn20106:15 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;5% US women, 9 women to 1 man diagnosed with fibromyalgia#bigonldn2010 #lowdosenaltrexone6:16 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Muscular pain, fatigue and insomnia are main symptoms as are joint pain and headaches. #bigonldn2010 #lowdosenaltrexone6:17 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;18 tender points, 11 are painful &lt; 4Kg/cm^2 Diagnosis difficultControversial condition. #lowdosenaltrexone #bigonldn2010 #FM#fibro6:18 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Microglia cells appear to play a role in #fibromyalgia Producce TNF, IL-6, Nitric Oxide and others #bigonldn2010 #lowdosenaltrexone6:20 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;When ill with flu, microglia cells are what produces ill feeling, tiredness and need to go to bed - useful for illness #bigonldn20106:21 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;In #fibromyalgia microglia perform this role when no illness / hypersensitive to normal situations in body #bigonldn2010#lowdosenaltrexone6:22 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;No existing drug modulates microglia but compounds exist which can do thisNIH research on this. #lowdosenaltrexone#bigonldn20106:25 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;See Linda Watkins research on microglia and #lowdosenaltrexone#fibromyalgia #bigonldn20106:26 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Theory - #lowdosenaltrexone binds to hyper-sensitive receptors on microglia6:28 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dr Jarred Younger's #lowdosenaltrexone fibromyalgia video presentationLive Q&amp;A later. #bigonldn2010http://yfrog.com/64x7hj6:37 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;New study - 30 women, mean age 43, no opiods, at least 6/10 on pain scale. #lowdosenaltrexone #bigonldn2010 #fibromyalgia6:39 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;70% of #fibromyalgia patients had improvement, 50% much or very much improved on #lowdosenaltrexone (50%-75% pain reduced)#bigonldn6:41 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;30% who had no improvement - ties in with 1st study, so consistent.#lowdosenaltrexone #bigonldn2010 #fibromyalgia6:42 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;15% reduction in pain from placebo, additional 15% reduction due to #lowdosenaltrexone #bigonldn2010 #fibromyalgia6:43 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;It seems that improvement persists to some extent even after#lowdosenaltrexone withdrawn. #fibromyalgia #bigonldn20106:44 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone tolerability = 89%, same as placebo in this#fibromyalgia studySo well very tolerated. #bigonldn20106:48 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone vivid dreams side-effect - 20% on placebo, 47% on LDN #bigonldn2010 Seldom disturbing dreams and tends to fade.6:49 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;1 person dropped out of study and 1 person reduced from 5 to 3mg and did well on that. #lowdosenaltrexone #bigonldn20106:50 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Next steps - Further anlyses, long-term safety, mechanistic proof, optimisation #lowdosenaltrexone #fibromyalgia #bigonldn20106:51 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Researchers looking at levo-naltrexone and dextro-naltrexone (Left and Right parts of molecule) to optimise #lowdosenaltrexone#bigonldn20106:54 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Des from Fibromyalgia UK 'Very positive' on the new study results.#lowdosenaltrexone #bigonldn20106:55 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Skype link up with Dr Jarred Younger for Q&amp;A being set-up now.#bigonldn2010 #lowdosenaltrexone #fibromyalgia6:59 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly "#lowdosenaltrexone out of system in 18 hours" "Could be that effect is longer lasting" (Slow return of symptoms)#bigonldn20107:02 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly "Study ties in with clinical experience" #bigonldn2010#lowdosenaltrexone #fibromyalgia7:03 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly Talk of Levo/Dextro Naltrexone suggests pharma could make money out of new #Naltrexone-derived drug#bigonldn20107:04 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly - Dextro-Naltrexone appears to be anti-inflammatory but not opiate receptor blooking #bigonldn2010#lowdosenaltrexone7:06 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dr Jarred Younger - #lowdosenaltrexone and #fibromyalgia fatigue data mirrored the fatigue results very closely. #bigonldn20107:11 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dosage was given 1 hour before retiring, 1 or 2 during day due to sleep problems. #lowdosenaltrexone #fibromyalgia #bigonldn20107:13 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Process of licensing levo and dextro naltrexone will take 'years'#bigonldn2010 #lowdosenaltrexone7:18 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@diamonDie presenting next on CFS/ME. #bigonldn2010 #CFS#ME #lowdosenaltrexone7:21 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;People with CFS/ME often have many other infections and disease including auto-immune disease #bigonldn2010 #lowdosenaltrexone7:23 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Adrenal and other endocrine issues are also common#bigonldn2010 #lowdosenaltrexone7:23 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Symptoms started one day, fatigue, fever, hives, IBS, nausea, pain - feverish to this day #bigonldn2010 #lowdosenaltrexone7:24 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Even the smallest exertion required 24 hour restIn Finland CFS/ME is not recognised as an illness and virtually no treatment#bigonldn20107:25 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;First heard of #lowdosenaltrexone in 2004, prescription in 2007 from Dr who had never heard of LDN #bigonldn20107:26 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Improvement in CFS/ME fatigue within 24 hours of#lowdosenaltrexone Much improved in first week, fever reduced#bigonldn20107:27 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Maija's Dr now treats many of his patients with #lowdosenaltrexoneImprovements reported from 50-70% improvement #bigonldn20107:28 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Patient - Could only walk '50m' now '3Km' Pain killers every day, now 1 every 2 weeks #lowdosenaltrexone #bigonldn20107:29 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone most effective for #CFS/ME but other drugs can help too. #bigonldn20107:31 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;"Don't believe people who say there are no treatments [for CFS/ME]" #bigonldn2010 #lowdosenaltrexone7:32 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Maija's book on Amazon - http://bit.ly/coFtLV #bigonldn2010#lowdosenaltrexone #CFS/ME7:33 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Next up - Christine Fowler Chronic Fatigue Syndrome patient.#bigonldn2010 #lowdosenaltrexone7:36 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Don't let @diamondie fool you - she did great!7:36 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Christine on #lowdosenaltrexone - Now active, back to work as normal and much, much improvedLess tired. #bigonldn2010#CFS/ME7:38 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;After 12 years of #CFS/ME on 75mg #lowdosenaltrexonerecommending anyone try it, 'shouting from the rooftops'#bigonldn20107:39 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Negatives - Memory still less effective and still more stressed than before #lowdosenaltrexoe #CFS/ME7:40 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly now on #CCSVI and #lowdosenaltrexone as complimentary therapies. #bigonldn20108:10 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Dr Tom believes CCSVI may feed into fibromyalgia and CFS/MS too#bigonldn2010 #lowdosenaltrexone8:13 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Chronic Cerebrospinal Venous Insufficiency - newly identified venous conditionInternational Union of Phlebology 2009#bigonldn20108:14 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;IUoP voted that #CCSVI was new condition #bigonldn20108:15 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly presenting on CCSVI and #lowdosenaltrexone#bigonldn2010 http://yfrog.com/bavo4j8:18 AM Apr 24th via Tweetie &lt;br /&gt;&lt;br /&gt;Iron Deposition in brain seen in dementia/Parkinson's and MS also in scans. #bigonldn2010 #CCSVI8:21 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Zivadino et al - Amount of iron deposits related to severity of MS, April 2010 #CCSVI #bigonldn20108:22 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Unlike #lowdosenaltrexone the MS Society in Italy are funding research (UK one isn't) and researchers are engaged.#bigonldn2010 #CCSVI8:24 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Zamboni April 2009 #CCSVI found in 90% of #MS patients studied.#bigonldn20108:25 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Zamboni Dec 2009 65 MS patient, 50% reduction in MRI lesions#CCSVI #bigonldn20108:26 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@rachelcreative Glad you're following and enjoying today.#bigonldn20108:27 AM Apr 24th via web in reply to rachelcreative &lt;br /&gt;&lt;br /&gt;Zivadinov 2010 - 38% patients with single MS episode had CCSVI; 22% of non MS patients CCSVI ; 80% of severe MS patients CCSVI#bigonldn20108:29 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Doppler scan better than MRI for visualising #CCSVI#bigonldn20108:31 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;A stent is a life-long procedure and complications can be serious - Venous stent can migrate to the heart #CCSVI #bigonldn20108:32 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;CT Venogram is chosen imaging method by @tomgilhooly for#CCSVI #bigonldn20108:33 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI and #lowdosenaltrexone - CCSVI is a distinct conditionIron deposit, blood/brain barrier breakdown. #bigonldn20108:34 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#lowdosenaltrexone immune modulator #CCSVI reduce immune stimulationNutrition important too. #bigonldn @tomgilhooly8:35 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#MS nutrition recommendations - Omega 3, Vitamin D, dairy-free, Inosine (Cut down Omega 6) #bigonldn2010 @tomgilhooly8:37 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI - larger group of patients interested than in#lowdosenaltrexone #bigonldn20108:37 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI - new condition ; Co-exists with #MS Treatment complements #lowdosenaltrexone #bigonldn2010 @tomgilhooly8:39 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI risks - greatest with stent + blood thinners but still low.#bigonldn2010 @tomgilhooly8:42 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI risks - new condition but treatment procedure is not a new one, proven. #bigonldn2010 @tomgilhooly8:43 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI treatment very over-subscribed, a waiting list is going to be created@tomgilhooly #bigonldn20108:43 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI procedure from @tomgilhooly will be cheaper than going to Poland for treatment. #bigonldn20108:47 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;#CCSVI ultimate aim is to get procedure on the NHS in UK but need data #bigonldn2010 @tomgilhooly8:47 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;RT @nobleday: @LDNNow SAM-e is another useful suppliment.8:55 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@fuwoyips EU #lowdosenaltrexone conference coverage at#bigonldn2010 hashtag8:56 AM Apr 24th via web in reply to fuwoyips &lt;br /&gt;&lt;br /&gt;2nd European #lowdosenaltrexone conference coming to and endThanks for reading the coverage and see you again next year.#bigonldn20109:00 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;@tomgilhooly #lowdosenaltrexone momentum from patients 'unstopable' #bigonldn20109:01 AM Apr 24th via web &lt;br /&gt;&lt;br /&gt;Crohn's disease costs New Zealand ~ $74 milion a year in healthcare costs for around 100,000 patients.A case for#lowdosenaltrexone? #ldnnowabout 22 hours ago via web &lt;br /&gt;&lt;br /&gt;Patient with Hashimoto's on #lowdosenaltrexone -http://proposals.yourcountryyourcall.com/ct/ct_a_view_idea.bix?i=58C09504about 19 hours ago via web &lt;br /&gt;&lt;br /&gt;@YahooAnswersNow See @LDNNow tweets from the European#lowdosenaltrexone conference#bigonldn2010 Fibro trial results published #ldnnowabout 13 hours ago via web in reply to YahooAnswersNow&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8270218232255901820?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8270218232255901820/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/04/2nd-european-low-dose-naltrexone.html#comment-form' title='3 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8270218232255901820'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8270218232255901820'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/04/2nd-european-low-dose-naltrexone.html' title='2nd European Low Dose Naltrexone Conference Summary'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>3</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4845744454614220347</id><published>2010-03-04T12:38:00.000-08:00</published><updated>2010-03-04T12:42:32.010-08:00</updated><title type='text'>Scottish Parliament Low Dose Naltrexone (LDN) NHS Availability Petition Update</title><content type='html'>The petition to the Scottish Parliament Public Petitions Committee, calling on the Scottish Government to ensure that Low Dose Naltrexone (LDN) to be made available to all on the NHS has passed its first milestone.&lt;br /&gt;At the second meeting considering it, the committee accepted the petition cannot be closed and continues to be pursued.&lt;br /&gt;The committee are writing to the Department of Health and The Scottish Government.&lt;br /&gt;&lt;br /&gt;You can view the question being asked of these bodies here -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNQs"&gt;http://bit.ly/SPLDNQs&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;All the documents received by the committee in response to their first round of correspondence are here -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNdocs"&gt;http://bit.ly/SPLDNdocs&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4845744454614220347?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4845744454614220347/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/03/scottish-parliament-low-dose-naltrexone.html#comment-form' title='11 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4845744454614220347'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4845744454614220347'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/03/scottish-parliament-low-dose-naltrexone.html' title='Scottish Parliament Low Dose Naltrexone (LDN) NHS Availability Petition Update'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>11</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3217347488061809975</id><published>2010-03-04T12:31:00.000-08:00</published><updated>2010-03-04T12:33:29.761-08:00</updated><title type='text'>The 2nd European Low Dose Naltrexone (LDN) Conference, Glasgow 24th April</title><content type='html'>You can register for the 2nd EU LDN Conference here -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.bigonldn2010.com/"&gt;http://www.bigonldn2010.com/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Watch the introductory video by Dr Tom Gilhooly where he talks of the work of LDN Now coming out of the 2009 conference&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ldnnow.com"&gt;http://ldnnow.com&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3217347488061809975?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3217347488061809975/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/03/2nd-european-low-dose-naltrexone-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3217347488061809975'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3217347488061809975'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/03/2nd-european-low-dose-naltrexone-ldn.html' title='The 2nd European Low Dose Naltrexone (LDN) Conference, Glasgow 24th April'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3094744565736614416</id><published>2010-01-28T01:16:00.001-08:00</published><updated>2010-01-28T01:24:56.114-08:00</updated><title type='text'>Great New Low Dose Naltrexone (LDN) Science Site</title><content type='html'>A brilliant one-stop resource for scientific information on Low Dose Naltrexone (LDN).&lt;br /&gt;A good one to give to skeptical doctors.&lt;br /&gt;&lt;br /&gt;There's a newsletter you can sign up to too.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ldnscience.org"&gt;http://www.ldnscience.org&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3094744565736614416?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3094744565736614416/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/01/great-new-low-dose-naltrexone-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3094744565736614416'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3094744565736614416'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/01/great-new-low-dose-naltrexone-ldn.html' title='Great New Low Dose Naltrexone (LDN) Science Site'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7867247964547815530</id><published>2010-01-07T14:26:00.001-08:00</published><updated>2010-01-07T14:50:35.877-08:00</updated><title type='text'>NEW European Parliament Level Petition for Low Dose Naltrexone Research Funding</title><content type='html'>Please consider signing this petition and passing it on. &lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight:bold;"&gt;NOTE&lt;/span&gt; - NO donation is required to the petition site, after filling in your details on the first page you have signed the petition and can leave the site without donating. Any donations that are made do not go to LDN Now or the EU government but rather to the petitions site.&lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight:bold;"&gt;NOTE&lt;/span&gt; - This petition is open to anyone, anywhere, not just EU citizens.&lt;br /&gt;&lt;br /&gt;Thanks.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.ipetitions.com/petition/ldnnow/"&gt;http://www.ipetitions.com/petition/ldnnow/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7867247964547815530?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7867247964547815530/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/01/new-european-parliament-level-petition.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7867247964547815530'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7867247964547815530'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2010/01/new-european-parliament-level-petition.html' title='NEW European Parliament Level Petition for Low Dose Naltrexone Research Funding'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7106254127231513269</id><published>2009-12-21T23:46:00.001-08:00</published><updated>2009-12-21T23:46:11.029-08:00</updated><title type='text'>UK Government Response to the LDN Now 13,000 Signature NHS Low Dose Naltrexone Trial Petition to Gordon Brown, UK Prime Minister, Gordon Brown</title><content type='html'>Link - &lt;a href="http://www.number10.gov.uk/Page21825"&gt;http://www.number10.gov.uk/Page21825&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Text -&lt;br /&gt;&lt;br /&gt;All drugs need to be thoroughly tested to make sure they are safe enough to be made available to patients.  Most research of this kind is done by the pharmaceutical industry.  The Government is aware that occasionally there will be few or no commercial incentives for companies to fund clinical trials. &lt;br /&gt;&lt;br /&gt;The Department of Health’s National Institute for Health Research (NIHR) supports the research most likely to bring benefits to patients and to the NHS.  High quality proposals for support into any aspect of human health are always welcome.  The NIHR Health Technology Assessment programme in particular is keen to receive suggestions for research topics in areas of market failure.  These can be sent through the open access form at: www.hta.ac.uk/suggest/index.shtml.      &lt;br /&gt;&lt;br /&gt;To date, no application has been received regarding low dose naltrexone.  Any application would be considered on its merits.&lt;br /&gt;&lt;br /&gt;----&lt;br /&gt;&lt;br /&gt;Author's Note - There is reason to suspect the sbove is not factually correct and that one application has been made. More news to follow later.&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7106254127231513269?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7106254127231513269/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/uk-government-response-to-ldn-now-13000.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7106254127231513269'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7106254127231513269'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/uk-government-response-to-ldn-now-13000.html' title='UK Government Response to the LDN Now 13,000 Signature NHS Low Dose Naltrexone Trial Petition to Gordon Brown, UK Prime Minister, Gordon Brown'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-6797104465894158251</id><published>2009-12-12T03:39:00.001-08:00</published><updated>2009-12-12T03:40:47.267-08:00</updated><title type='text'>Audit Scotland Warns of Pressures on the NHS Scotland Budget - Low Dose Naltreonxe (LDN) Savings Cannot be Ignored</title><content type='html'>And so it goes on, yet another reason why the 4000%+ higher price of currently used auto-immune and cancer treatments vs Low Dose Naltrexone (LDN) cannot be ignored any longer. The potential billions of pounds in savings here make the millions required for LDN clinical trials a sound investment for the NHS in Scotland and the UK as a whole.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNcost"&gt;http://bit.ly/SPLDNcost&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-6797104465894158251?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/6797104465894158251/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/audit-scotland-warns-of-pressures-on.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/6797104465894158251'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/6797104465894158251'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/audit-scotland-warns-of-pressures-on.html' title='Audit Scotland Warns of Pressures on the NHS Scotland Budget - Low Dose Naltreonxe (LDN) Savings Cannot be Ignored'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5900828346319201195</id><published>2009-12-12T03:33:00.001-08:00</published><updated>2009-12-12T03:33:57.822-08:00</updated><title type='text'>UK Telegraph - NICE Propose to Restrict Key IBD Treatments to One Year on Grounds of Cost</title><content type='html'>Yet more justification, if any were needed that the UK NHS needs to seriously look into widespread use of Low Dose Naltrexone (LDN) as a low cost treatment for Crohn's Disease, Ulcerative Colitis and the any other conditions it has been used successfully to reat including other auto-immune disease, cancers, autism and HIV/AIDs.&lt;br /&gt;&lt;br /&gt;At £12,500 per patient per year for Infliximab versus £300 per year for Low Dose Naltrexone, it is the proverbial 'no-brainer' for the NHS to do whatever it takes to convince consultants and GPs that LDN is a suitable drug choice for IBD.&lt;br /&gt;&lt;br /&gt;The government and public bodies need to cease dithering on this and take action now so that IBD sufferers need not suffer unnecessarily.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/NICEIBD&lt;br /&gt;"&gt;http://bit.ly/NICEIBD&lt;br /&gt;&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5900828346319201195?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5900828346319201195/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/uk-telegraph-nice-propose-to-restrict.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5900828346319201195'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5900828346319201195'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/uk-telegraph-nice-propose-to-restrict.html' title='UK Telegraph - NICE Propose to Restrict Key IBD Treatments to One Year on Grounds of Cost'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8875768089594900988</id><published>2009-12-08T14:01:00.001-08:00</published><updated>2009-12-08T14:01:52.413-08:00</updated><title type='text'>Round-Up of LDN Now Low Dose Naltrexone Campaign at The Scottish Parliament Public Petitions Committee</title><content type='html'>Original video of the meeting here (Click link 01/12/2009 and fast forward 39 minutes to LDN Now meeting) -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNvid1"&gt;http://bit.ly/SPLDNvid1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;youtube version - &lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNvid"&gt;http://bit.ly/SPLDNvid&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Interview segment from Holyrood TV Highlights programme (Click link 03/12/2009 and fast forward to 16:00 minutes) -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNint"&gt;http://bit.ly/SPLDNint&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Full transcript of the meeting -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNmin"&gt;http://bit.ly/SPLDNmin&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8875768089594900988?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8875768089594900988/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/round-up-of-ldn-now-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8875768089594900988'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8875768089594900988'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/round-up-of-ldn-now-low-dose-naltrexone.html' title='Round-Up of LDN Now Low Dose Naltrexone Campaign at The Scottish Parliament Public Petitions Committee'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1182210761993633505</id><published>2009-12-05T00:51:00.001-08:00</published><updated>2009-12-05T00:51:18.775-08:00</updated><title type='text'>Minute from the LDN Now Scotland Scottish Parliament meeting on Low Dose Naltrexone (LDN) Availability on the NHS in Scotland</title><content type='html'>The first minute of the meeting is available here - &lt;a href="http://bit.ly/SPLDNmin1"&gt;http://bit.ly/SPLDNmin1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Some key quotes (Paraphrased)&lt;br /&gt;&lt;br /&gt;Robin Harper, (Scottish Green Party) - Basis for clinical trial exists with current LDN evidence. Suggest GPs gather clinical data on LDN use.&lt;br /&gt;&lt;br /&gt;Anne McLaughlin (SNP) - Committee needs to write to charities to ask if they will help fund trials.&lt;br /&gt;&lt;br /&gt;Nigel Don (SNP) - LDN is a drug that treats the immune system drug and clinical trials are required for all conditions it can be shown to treat.&lt;br /&gt;&lt;br /&gt;John Wilson (SNP) - Health charities should be encouraged to ensure they are spending money on researching all options for their patients, including LDN.&lt;br /&gt;&lt;br /&gt;Frank McAveety (Labour) - The issue that the private sector will not fund trials due to no profit motive is clear and is noted.&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1182210761993633505?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1182210761993633505/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/minute-from-ldn-now-scotland-scottish.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1182210761993633505'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1182210761993633505'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/minute-from-ldn-now-scotland-scottish.html' title='Minute from the LDN Now Scotland Scottish Parliament meeting on Low Dose Naltrexone (LDN) Availability on the NHS in Scotland'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5751812426687213803</id><published>2009-12-05T00:45:00.000-08:00</published><updated>2009-12-05T00:46:47.524-08:00</updated><title type='text'>Low Dose Naltrexone (LDN) Database - Update</title><content type='html'>If you are using, or have used Low Dose Naltrexone (LDN), please take 2 minutes to enter or update your experience of the drug on the LDN Database web site - &lt;a href="http://ldndatabase.com"&gt;LDN Database .com&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Thanks to John Donnelly of LDN Now Ireland for this great resource, http://ldnnow.com&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5751812426687213803?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5751812426687213803/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/low-dose-naltrexone-ldn-database-update.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5751812426687213803'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5751812426687213803'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/low-dose-naltrexone-ldn-database-update.html' title='Low Dose Naltrexone (LDN) Database - Update'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3931723125972162700</id><published>2009-12-02T02:13:00.001-08:00</published><updated>2009-12-02T08:26:19.886-08:00</updated><title type='text'>Low Dose Naltrexone (LDN) at The Scottish Parliament</title><content type='html'>LDN had what could be it's most public hearing yet at possibly the hightest political level too, at The Scottish Parliament Public Petitions Committee.&lt;br /&gt;Video is available here -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/SPLDNvid1"&gt;http://bit.ly/SPLDNvid1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Click the 01/12/2009 link and the LDN petition starts at around 40 minutes in.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;Hopefully more to follow on the outcome of this committee's investigations into LDN and the NHS in Scotland.&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3931723125972162700?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3931723125972162700/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/low-dose-naltrexone-ldn-at-scottish.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3931723125972162700'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3931723125972162700'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/12/low-dose-naltrexone-ldn-at-scottish.html' title='Low Dose Naltrexone (LDN) at The Scottish Parliament'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4204498268693585187</id><published>2009-11-02T05:54:00.001-08:00</published><updated>2009-11-02T05:54:40.204-08:00</updated><title type='text'>Dr Ian Zagon's Introduction to Low Dose Naltrexone (LDN)</title><content type='html'>&lt;a href="http://www.ldnresearchtrustfiles.co.uk/docs/Dr%20Zagon.pdf"&gt;http://www.ldnresearchtrustfiles.co.uk/docs/Dr%20Zagon.pdf&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4204498268693585187?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4204498268693585187/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/11/dr-ian-zagons-introduction-to-low-dose.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4204498268693585187'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4204498268693585187'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/11/dr-ian-zagons-introduction-to-low-dose.html' title='Dr Ian Zagon&apos;s Introduction to Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4912412968024833862</id><published>2009-11-02T02:17:00.001-08:00</published><updated>2009-11-02T02:17:46.245-08:00</updated><title type='text'>A Lupus Patient's Experience with Low Dose Naltrexone (LDN)</title><content type='html'>&lt;a href="http://healingfromlupus.blogspot.com/2009/11/low-dose-naltrexone.html"&gt;http://healingfromlupus.blogspot.com/2009/11/low-dose-naltrexone.html&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4912412968024833862?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4912412968024833862/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/11/lupus-patients-experience-with-low-dose.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4912412968024833862'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4912412968024833862'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/11/lupus-patients-experience-with-low-dose.html' title='A Lupus Patient&apos;s Experience with Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1166667815825710871</id><published>2009-10-26T14:16:00.001-07:00</published><updated>2009-10-26T14:16:44.826-07:00</updated><title type='text'>Scots Multiple Sclerosis Patient's Blog on Her Low Dose Naltrexone Experience</title><content type='html'>Blog here -&lt;br /&gt;&lt;a href="http://bit.ly/UZBKv"&gt;http://bit.ly/UZBKv&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1166667815825710871?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1166667815825710871/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/scots-multiple-sclerosis-patients-blog.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1166667815825710871'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1166667815825710871'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/scots-multiple-sclerosis-patients-blog.html' title='Scots Multiple Sclerosis Patient&apos;s Blog on Her Low Dose Naltrexone Experience'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8179701549913295382</id><published>2009-10-26T04:54:00.001-07:00</published><updated>2009-10-26T04:54:27.513-07:00</updated><title type='text'>Glasgow Evening Times Story on LDN Now Campaign</title><content type='html'>&lt;a href=" http://www.eveningtimes.co.uk/news/display.var.2533158.0.plea_to_fund_drug_helping_ms_sufferers.php"&gt;&lt;br /&gt;http://www.eveningtimes.co.uk story&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8179701549913295382?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8179701549913295382/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/glasgow-evening-times-story-on-ldn-now.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8179701549913295382'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8179701549913295382'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/glasgow-evening-times-story-on-ldn-now.html' title='Glasgow Evening Times Story on LDN Now Campaign'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-9115219230399472929</id><published>2009-10-23T11:56:00.000-07:00</published><updated>2009-10-23T11:57:25.474-07:00</updated><title type='text'>US TV Al Gorman on Low Dose Naltrexone</title><content type='html'>&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/EodqDy1DxoE&amp;hl=en&amp;fs=1&amp;"&gt;&lt;/param&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;/param&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;/param&gt;&lt;embed src="http://www.youtube.com/v/EodqDy1DxoE&amp;hl=en&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-9115219230399472929?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/9115219230399472929/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/us-tv-al-gorman-on-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/9115219230399472929'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/9115219230399472929'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/us-tv-al-gorman-on-low-dose-naltrexone.html' title='US TV Al Gorman on Low Dose Naltrexone'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4394124113933476688</id><published>2009-10-22T13:41:00.001-07:00</published><updated>2009-10-22T13:41:12.919-07:00</updated><title type='text'>Mike Lucas on Low Dose Naltrexone</title><content type='html'>Michael Moore's colleague Mike Lucas weighs on the Low Dose Naltrexone issue -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://fight4thepeople.wordpress.com/2009/10/"&gt;Why won’t the drug companies shell out cash for a promising drug that requires FDA approval?&lt;br /&gt;&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4394124113933476688?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4394124113933476688/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/mike-lucas-on-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4394124113933476688'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4394124113933476688'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/10/mike-lucas-on-low-dose-naltrexone.html' title='Mike Lucas on Low Dose Naltrexone'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-630451880094845403</id><published>2009-09-17T05:28:00.001-07:00</published><updated>2009-09-17T05:40:02.329-07:00</updated><title type='text'>LDN Now Day is a Success Story</title><content type='html'>Last Saturday volunteers, patients and their friends were out on streets around the UK collecting signatures for the Number 10 Downing Street petition to encourage the UK NHS to fund trials of Low Dose Naltrexone so that every NHS patient has the option of Low Dose Naltrexone treatment on the NHS.&lt;br /&gt;&lt;br /&gt;The day was a big success, around 3000 signatures have been collected, which when the site is updated will bring the total to around 7400 signatures.&lt;br /&gt;&lt;br /&gt;As things stand at the moment, the petition is number 5 in the Health category and should move to 4 within the week.&lt;br /&gt;In the overall list of all petitions it is number 24 and should be in the top 20 by the end of the week.&lt;br /&gt;&lt;br /&gt;So, if you are a UK citizen and have yet to sign up, please do so now. If you have already signed up, please encourage at least 10 of your friends to sign up now and make this petition one that the UK Government cannot ignore.&lt;br /&gt;&lt;br /&gt;The recent apology by Gordon Brown for Alan Turing's treatment shows that these petitions do count, so make your voice heard now. Save the NHS millions, if not billions, help improve millions of patents quality of life and health and let the government know that you will not let your health be dictated by the patent system and pharmaceutical companies profits.&lt;br /&gt;&lt;br /&gt;Sign now - &lt;a href="http://tinyurl.com/ldnnowpet"&gt;http://tinyurl.com/ldnnowpet&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Write to your MP about Low Dose Naltrexone - http://writetothem.org&lt;br /&gt;&lt;br /&gt;Find out more - &lt;a href="http://lowdosenaltrexone.org"&gt;http://lowdosenaltrexone.org&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ldnnow.com"&gt;http://ldnnow.com&lt;/a&gt;&lt;br /&gt;&lt;a href="http://ldnresearchtrust.org"&gt;http://ldnresearchtrust.org&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;a href="http://ldnhelp.com"&gt;http://ldnhelp.com&lt;/a&gt;&lt;br /&gt;&lt;a href="http://ldndatabase.com"&gt;http://ldndatabase.com&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-630451880094845403?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/630451880094845403/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/ldn-now-day-is-success-story.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/630451880094845403'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/630451880094845403'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/ldn-now-day-is-success-story.html' title='LDN Now Day is a Success Story'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4419513264993753130</id><published>2009-09-16T13:06:00.001-07:00</published><updated>2009-09-16T13:06:39.983-07:00</updated><title type='text'>Mary Boyle Bradley LDN Radio Show</title><content type='html'>A Low Dose Naltrexone podcast -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.blogtalkradio.com/Mary-Boyle-Bradley"&gt;http://www.blogtalkradio.com/Mary-Boyle-Bradley&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="itpc://www.blogtalkradio.com/Mary-Boyle-Bradley.rss"&gt;Subscribe via iTunes&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;The latest episode focusses on an interview with Celia Danks of &lt;a hef="http://ldnow.com"&gt;LDN Now&lt;/a&gt; who beat Cancer and IBS with Low Dose Naltrexone.&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4419513264993753130?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4419513264993753130/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/mary-boyle-bradley-ldn-radio-show.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4419513264993753130'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4419513264993753130'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/mary-boyle-bradley-ldn-radio-show.html' title='Mary Boyle Bradley LDN Radio Show'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8416680150805104902</id><published>2009-09-11T13:01:00.000-07:00</published><updated>2009-09-11T13:02:06.666-07:00</updated><title type='text'>Video - Joseph Wouk - LDN (Low Dose Naltrexone) in 7 Minutes</title><content type='html'>&lt;object classid="clsid:D27CDB6E-AE6D-11cf-96B8-444553540000" width="437" height="371" id="viddler_a111f2b2"&gt;&lt;param name="movie" value="http://www.viddler.com/player/a111f2b2/" /&gt;&lt;param name="allowScriptAccess" value="always" /&gt;&lt;param name="allowFullScreen" value="true" /&gt;&lt;embed src="http://www.viddler.com/player/a111f2b2/" width="437" height="371" type="application/x-shockwave-flash" allowScriptAccess="always" allowFullScreen="true" name="viddler_a111f2b2"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8416680150805104902?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8416680150805104902/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/video-joseph-wouk-ldn-low-dose.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8416680150805104902'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8416680150805104902'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/video-joseph-wouk-ldn-low-dose.html' title='Video - Joseph Wouk - LDN (Low Dose Naltrexone) in 7 Minutes'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5669313270109623399</id><published>2009-09-10T14:09:00.001-07:00</published><updated>2009-09-10T14:09:33.257-07:00</updated><title type='text'>Joseph Wouk Video - Supporting LDN Now Day 12th September 2009</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande', sans-serif; font-size: 14px; color: rgb(61, 25, 87); line-height: 15px; "&gt;&lt;a href="http://www.viddler.com/explore/josephwouk/videos/41/"&gt;http://www.viddler.com/explore/josephwouk/videos/41/&lt;/a&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5669313270109623399?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5669313270109623399/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/joseph-wouk-video-supporting-ldn-now.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5669313270109623399'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5669313270109623399'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/joseph-wouk-video-supporting-ldn-now.html' title='Joseph Wouk Video - Supporting LDN Now Day 12th September 2009'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-9103211994918535464</id><published>2009-09-07T14:07:00.001-07:00</published><updated>2009-09-07T14:10:51.701-07:00</updated><title type='text'>ITV's This Morning GP, Dr Chris Steele on Low Dose Naltrexone (LDN)</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span"  style="font-family:Verdana, Geneva, Arial, Helvetica, sans-serif;"&gt;&lt;span class="Apple-style-span" style="font-size: -webkit-xxx-large; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"&gt;&lt;b&gt;&lt;span class="Apple-style-span"   style="font-family:Georgia, serif;font-size:130%;"&gt;&lt;span class="Apple-style-span" style="font-size: 16px; font-weight: normal; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px;"&gt;Link - &lt;span class="Apple-style-span"   style="font-weight: bold; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px; font-family:Verdana, Geneva, Arial, Helvetica, sans-serif;font-size:13px;"&gt;&lt;a href="http://tinyurl.com/DrCLDN"&gt;http://tinyurl.com/DrCLDN&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"  style="font-family:Verdana, Geneva, Arial, Helvetica, sans-serif;"&gt;&lt;span class="Apple-style-span" style="font-size: -webkit-xxx-large; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"   style="font-family:Verdana, Geneva, Arial, Helvetica, sans-serif;font-size:100%;"&gt;&lt;span class="Apple-style-span"  style=" -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;font-size:13px;"&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;br /&gt;&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/CVpjsDK0LPA&amp;amp;hl=en&amp;amp;fs=1&amp;amp;"&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;embed src="http://www.youtube.com/v/CVpjsDK0LPA&amp;amp;hl=en&amp;amp;fs=1&amp;amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-9103211994918535464?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/9103211994918535464/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/itvs-this-morning-gp-dr-chris-steele-on.html#comment-form' title='2 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/9103211994918535464'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/9103211994918535464'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/09/itvs-this-morning-gp-dr-chris-steele-on.html' title='ITV&apos;s This Morning GP, Dr Chris Steele on Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4580428540120526589</id><published>2009-08-10T13:55:00.000-07:00</published><updated>2009-08-10T13:56:07.914-07:00</updated><title type='text'>New Low Dose Naltrexone (LDN) Awareness Site in German</title><content type='html'>&lt;span class="Apple-style-span"   style="font-family:'Lucida Grande', fantasy;font-size:100%;"&gt;&lt;span class="Apple-style-span" style="font-size: 11px; white-space: pre;"&gt;&lt;a href="http://www.ldnhilft.org/"&gt;http://www.ldnhilft.org/&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4580428540120526589?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4580428540120526589/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/08/new-low-dose-naltrexone-ldn-awareness.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4580428540120526589'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4580428540120526589'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/08/new-low-dose-naltrexone-ldn-awareness.html' title='New Low Dose Naltrexone (LDN) Awareness Site in German'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7442853175281635433</id><published>2009-07-31T14:42:00.001-07:00</published><updated>2009-07-31T14:42:59.649-07:00</updated><title type='text'>Petition - National Health Funding for Low Dose Naltrexone in Australia</title><content type='html'>&lt;a href="http://www.gopetition.com/online/28354.html"&gt;&lt;/a&gt;&lt;a href="http://www.gopetition.com/online/28354.html"&gt;http://www.gopetiti on.com/online/ 28354.html&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style="font-weight: bold; "&gt;National Health Funding for Low Dose Naltrexone in Australia&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Published by Trevor George Stephens&lt;br /&gt;Date: Jun 06, 2009&lt;br /&gt;Category: Health&lt;br /&gt;Region: Australia&lt;br /&gt;Target: Cancer sufferers MS sufferers and HIV+ persons&lt;br /&gt;Web site:&lt;a href="http://www.lowdosenaltrexone.org/"&gt; &lt;/a&gt;&lt;a href="http://www.lowdosenaltrexone.org/"&gt;http://www.lowdosen altrexone. org/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7442853175281635433?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7442853175281635433/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/petition-national-health-funding-for.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7442853175281635433'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7442853175281635433'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/petition-national-health-funding-for.html' title='Petition - National Health Funding for Low Dose Naltrexone in Australia'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7347911904366919181</id><published>2009-07-27T13:04:00.000-07:00</published><updated>2009-07-27T13:05:13.964-07:00</updated><title type='text'>Low Dose Naltrexone (LDN) Dose Timing</title><content type='html'>&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://ms.about.com/b/2009/07/20/julies-low-dose-naltrexone-faqs-dose-timing.htm"&gt;http://ms.about.com/b/2009/07/20/julies-low-dose-naltrexone-faqs-dose-timing.htm&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7347911904366919181?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7347911904366919181/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/low-dose-naltrexone-ldn-dose-timing.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7347911904366919181'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7347911904366919181'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/low-dose-naltrexone-ldn-dose-timing.html' title='Low Dose Naltrexone (LDN) Dose Timing'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-6536426265448135115</id><published>2009-07-27T12:50:00.000-07:00</published><updated>2009-07-27T12:58:11.373-07:00</updated><title type='text'>UK LDN Now Day - Saturday 12th September 2009</title><content type='html'>On LDN Now Day, volunteers will be soliciting signatures for the Number 10 LDN Petition -&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://petitions.number10.gov.uk/LowDNaltrexone/"&gt;http://petitions.number10.gov.uk/LowDNaltrexone/&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;Read more on the LDN Now Blog here -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://ldnnow.co.uk/8601.html?entryId=4c926df35035815d4caacb2f4a7a11c0"&gt;http://ldnnow.co.uk/8601.html?entryId=4c926df35035815d4caacb2f4a7a11c0&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;And search for &lt;a href="http://twitter.com/#search?q=ldnnowday"&gt;#ldnnowday&lt;/a&gt; on twitter for more info as it is available.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://twitter.com/LD_Naltrexone"&gt;http://twitter.com/LD_Naltrexone&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-6536426265448135115?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/6536426265448135115/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/uk-ldn-now-day-saturday-12th-september.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/6536426265448135115'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/6536426265448135115'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/uk-ldn-now-day-saturday-12th-september.html' title='UK LDN Now Day - Saturday 12th September 2009'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-394284575671442654</id><published>2009-07-26T06:23:00.000-07:00</published><updated>2009-07-26T06:26:21.739-07:00</updated><title type='text'>Multiple Sclerosis Drug Prices and Low Dose Naltrexone (LDN)</title><content type='html'>Looking at this article about MS drug prices in the US really brings it home how much the UK NHS could save using Low Dose Naltrexone (LDN) for MS treatment -&lt;br /&gt;&lt;br /&gt;"&lt;br /&gt;&lt;ul&gt;&lt;li&gt;Avonex (was $10,000/year): Minimum price = $23,736; Maximum price = $30,660&lt;/li&gt;&lt;li&gt;Betaseron (was $10,000/year): Minimum price = $22,272; Maximum price = $32,616&lt;/li&gt;&lt;li&gt;Copaxone (was $10,000/year): Minimum price = $23,208; Maximum price = $33,804&lt;/li&gt;&lt;li&gt;Rebif was (was $15,600/year): Minimum price = $25,068; Maximum price = $30,756&lt;/li&gt;&lt;li&gt;Tysabri (was $28,400/year): Now costs 31,332 for the drug itself, with additional charges for the infusion facility or clinic fees."&lt;/li&gt;&lt;/ul&gt;Article -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ms.about.com/b/2009/07/21/multiple-sclerosis-drug-prices-whoa.htm"&gt;http://ms.about.com/b/2009/07/21/multiple-sclerosis-drug-prices-whoa.htm&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-394284575671442654?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/394284575671442654/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/multiple-sclerosis-drug-prices-and-low.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/394284575671442654'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/394284575671442654'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/multiple-sclerosis-drug-prices-and-low.html' title='Multiple Sclerosis Drug Prices and Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4934185848844743257</id><published>2009-07-25T02:29:00.000-07:00</published><updated>2009-07-25T02:30:17.313-07:00</updated><title type='text'>Low Dose Naltrexonxe (LDN) on the Fourth Plinth, Trafalgar Square, London</title><content type='html'>&lt;a href="http://www.oneandother.co.uk/participants/Brian_L/"&gt;http://www.oneandother.co.uk/participants/Brian_L/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4934185848844743257?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4934185848844743257/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/low-dose-naltrexonxe-ldn-on-fourth.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4934185848844743257'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4934185848844743257'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/low-dose-naltrexonxe-ldn-on-fourth.html' title='Low Dose Naltrexonxe (LDN) on the Fourth Plinth, Trafalgar Square, London'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3021513043951814737</id><published>2009-07-24T14:14:00.000-07:00</published><updated>2009-07-24T14:15:24.804-07:00</updated><title type='text'>Video - Dr Bernard Bihari Interviewed on Low Dose Naltrexone (LDN)</title><content type='html'>&lt;object width="400" height="300"&gt;&lt;param name="allowfullscreen" value="true" /&gt;&lt;param name="allowscriptaccess" value="always" /&gt;&lt;param name="movie" value="http://vimeo.com/moogaloop.swf?clip_id=4547621&amp;amp;server=vimeo.com&amp;amp;show_title=1&amp;amp;show_byline=1&amp;amp;show_portrait=0&amp;amp;color=&amp;amp;fullscreen=1" /&gt;&lt;embed src="http://vimeo.com/moogaloop.swf?clip_id=4547621&amp;amp;server=vimeo.com&amp;amp;show_title=1&amp;amp;show_byline=1&amp;amp;show_portrait=0&amp;amp;color=&amp;amp;fullscreen=1" type="application/x-shockwave-flash" allowfullscreen="true" allowscriptaccess="always" width="400" height="300"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;p&gt;&lt;a href="http://vimeo.com/4547621"&gt;Low Dose Naltrexone&lt;/a&gt; from &lt;a href="http://vimeo.com/user1530876"&gt;Fertility Care&lt;/a&gt; on &lt;a href="http://vimeo.com"&gt;Vimeo&lt;/a&gt;.&lt;/p&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3021513043951814737?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3021513043951814737/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-dr-bernard-bihari-interviewed-on.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3021513043951814737'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3021513043951814737'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-dr-bernard-bihari-interviewed-on.html' title='Video - Dr Bernard Bihari Interviewed on Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5772270883915155279</id><published>2009-07-23T14:15:00.000-07:00</published><updated>2009-07-23T14:16:09.465-07:00</updated><title type='text'>Video - MS Patient on Symptom Improvement on Low Dose Naltrexone (LDN), Contrasted with Tysbari</title><content type='html'>&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/IYzmUxBzJ_4&amp;hl=en&amp;fs=1&amp;"&gt;&lt;/param&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;/param&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;/param&gt;&lt;embed src="http://www.youtube.com/v/IYzmUxBzJ_4&amp;hl=en&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5772270883915155279?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5772270883915155279/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-ms-patient-on-symptom-improvement.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5772270883915155279'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5772270883915155279'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-ms-patient-on-symptom-improvement.html' title='Video - MS Patient on Symptom Improvement on Low Dose Naltrexone (LDN), Contrasted with Tysbari'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3481180709619808345</id><published>2009-07-23T14:13:00.000-07:00</published><updated>2009-07-23T14:14:16.617-07:00</updated><title type='text'>Video - MS Patient on Low Dose Naltrexone (LDN) Stopping Progression</title><content type='html'>&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/bCp7rFgaqx0&amp;hl=en&amp;fs=1&amp;"&gt;&lt;/param&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;/param&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;/param&gt;&lt;embed src="http://www.youtube.com/v/bCp7rFgaqx0&amp;hl=en&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3481180709619808345?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3481180709619808345/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-ms-patient-on-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3481180709619808345'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3481180709619808345'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-ms-patient-on-low-dose-naltrexone.html' title='Video - MS Patient on Low Dose Naltrexone (LDN) Stopping Progression'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-334120183904961715</id><published>2009-07-23T14:10:00.001-07:00</published><updated>2009-07-23T14:10:28.896-07:00</updated><title type='text'>Video - Skip Lenz, LDN (Low Dose Naltrexone) Expert Pharmacist on LDN Side Effects (Lack of)</title><content type='html'>&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/YVdWY_SEFOk&amp;hl=en&amp;fs=1&amp;"&gt;&lt;/param&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;/param&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;/param&gt;&lt;embed src="http://www.youtube.com/v/YVdWY_SEFOk&amp;hl=en&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-334120183904961715?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/334120183904961715/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-skip-lenz-ldn-low-dose-naltrexone_23.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/334120183904961715'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/334120183904961715'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-skip-lenz-ldn-low-dose-naltrexone_23.html' title='Video - Skip Lenz, LDN (Low Dose Naltrexone) Expert Pharmacist on LDN Side Effects (Lack of)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5696048479969655308</id><published>2009-07-23T14:07:00.000-07:00</published><updated>2009-07-23T14:08:25.144-07:00</updated><title type='text'>Video - Skip Lenz, LDN (Low Dose Naltrexone) Expert Pharmacist</title><content type='html'>&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/HuIQcm1Ixmg&amp;hl=en&amp;fs=1&amp;"&gt;&lt;/param&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;/param&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;/param&gt;&lt;embed src="http://www.youtube.com/v/HuIQcm1Ixmg&amp;hl=en&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5696048479969655308?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5696048479969655308/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-skip-lenz-ldn-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5696048479969655308'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5696048479969655308'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-skip-lenz-ldn-low-dose-naltrexone.html' title='Video - Skip Lenz, LDN (Low Dose Naltrexone) Expert Pharmacist'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8609802335513483552</id><published>2009-07-23T14:05:00.000-07:00</published><updated>2009-07-23T14:06:05.958-07:00</updated><title type='text'>Video - 40 Year Crohn's Patient Tells of Her LDN Experience</title><content type='html'>&lt;object width="425" height="344"&gt;&lt;param name="movie" value="http://www.youtube.com/v/4hgwKIft5Ac&amp;hl=en&amp;fs=1&amp;"&gt;&lt;/param&gt;&lt;param name="allowFullScreen" value="true"&gt;&lt;/param&gt;&lt;param name="allowscriptaccess" value="always"&gt;&lt;/param&gt;&lt;embed src="http://www.youtube.com/v/4hgwKIft5Ac&amp;hl=en&amp;fs=1&amp;" type="application/x-shockwave-flash" allowscriptaccess="always" allowfullscreen="true" width="425" height="344"&gt;&lt;/embed&gt;&lt;/object&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8609802335513483552?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8609802335513483552/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-40-year-crohns-patient-tells-of.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8609802335513483552'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8609802335513483552'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/video-40-year-crohns-patient-tells-of.html' title='Video - 40 Year Crohn&apos;s Patient Tells of Her LDN Experience'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4237807674565969486</id><published>2009-07-22T01:08:00.002-07:00</published><updated>2009-07-22T01:13:07.008-07:00</updated><title type='text'>Low Dose Naltrexone (LDN) on The Fourth Plinth, Trafalgar Square, London, Friday July 22nd 2009</title><content type='html'>&lt;span class="status-body"&gt;&lt;span class="entry-content"&gt;This Friday, 22nd of July between 11:00-12:00, Brian Lonsdale will be on the Fourth Plinth in Trafalgar Square, London to focus attention on Low Dose Naltrexone and specifically, the Number 10 petition -&lt;br /&gt;&lt;br /&gt;&lt;a href="http://petitions.number10.gov.uk/LowDNaltrexone/"&gt;UK Government Petition for Low Dose Naltrexone Trial Funding&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;span class="status-body"&gt;&lt;span class="entry-content"&gt;&lt;br /&gt;&lt;a href="http://bit.ly/DibRO" rel="nofollow" target="_blank"&gt;Trafalgar Square, Fourth Plinth Web Site&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4237807674565969486?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4237807674565969486/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/low-dose-naltrexone-ldn-on-fourth.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4237807674565969486'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4237807674565969486'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/low-dose-naltrexone-ldn-on-fourth.html' title='Low Dose Naltrexone (LDN) on The Fourth Plinth, Trafalgar Square, London, Friday July 22nd 2009'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1059952924891668884</id><published>2009-07-22T01:08:00.001-07:00</published><updated>2009-07-22T01:08:15.106-07:00</updated><title type='text'>Milford Haven woman petitions government for LDN (Low Dose Naltrexone) trials</title><content type='html'>Article from The Western Telegraph Newspaper&lt;br /&gt;&lt;br /&gt;"Jayne Crocker and her partner Andrew Barnett are both prescribed low dose naltrexone (LDN). They say the generic drug has been used to successfully treat cancer, autoimmune systems and central nervous system disorders. "&lt;br /&gt;&lt;br /&gt;&lt;a href="http://bit.ly/EVfQm" rel="nofollow" target="_blank"&gt;&lt;span class="status-body"&gt;&lt;span class="entry-content"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;a&gt;http://bit.ly/EVfQm&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1059952924891668884?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1059952924891668884/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/milford-haven-woman-petitions.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1059952924891668884'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1059952924891668884'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/milford-haven-woman-petitions.html' title='Milford Haven woman petitions government for LDN (Low Dose Naltrexone) trials'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3761201279891548683</id><published>2009-07-22T01:04:00.000-07:00</published><updated>2009-07-22T01:06:08.894-07:00</updated><title type='text'>(MS) Sufferer joins in battle for trials of 'wonder drug' (Low Dose Naltrexone)</title><content type='html'>&lt;span class="status-body"&gt;&lt;span class="entry-content"&gt;Article from This Is South Wales web site -&lt;br /&gt;&lt;br /&gt;"&lt;/span&gt;&lt;/span&gt;The couple have created a petition to take their fight to 10 Downing Street, and have already gathered around 3,000 signatures.             &lt;p&gt;Mr Barnett, who has secondary progressive MS, said: "We urge the Government to fund a trial of LDN on the NHS."&lt;/p&gt;&lt;span class="status-body"&gt;&lt;span class="entry-content"&gt;&lt;br /&gt;&lt;a href="http://bit.ly/3Iy3sI"&gt; &lt;/a&gt;&lt;a href="http://bit.ly/3Iy3sI" rel="nofollow" target="_blank"&gt;http://bit.ly/3Iy3sI&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3761201279891548683?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3761201279891548683/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/ms-sufferer-joins-in-battle-for-trials.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3761201279891548683'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3761201279891548683'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/ms-sufferer-joins-in-battle-for-trials.html' title='(MS) Sufferer joins in battle for trials of &apos;wonder drug&apos; (Low Dose Naltrexone)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5581764752257372491</id><published>2009-07-10T00:47:00.000-07:00</published><updated>2009-07-10T00:51:00.850-07:00</updated><title type='text'>MS Patient Blog - On Low Dose Naltrexone (LDN) She Forgets She Has MS</title><content type='html'>&lt;span style="font-size:100%;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;The latest installment of  &lt;/span&gt;&lt;/span&gt;Julie  Stachowiak, Ph.D.&lt;span style="font-size:100%;"&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;'s Low Dose Naltrexone experience with Relapsing Remitting Multiple Sclerosis.&lt;br /&gt;&lt;br /&gt;In this entry Julie says that, at times she is starting to forget she has MS due to the beneficial effect of LDN.&lt;/span&gt;&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ms.about.com/b/2009/07/07/julies-low-dose-naltrexone-journal-month-2-5.htm"&gt;http://ms.about.com/b/2009/07/07/julies-low-dose-naltrexone-journal-month-2-5.htm&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5581764752257372491?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5581764752257372491/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/ms-patient-blog-on-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5581764752257372491'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5581764752257372491'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/ms-patient-blog-on-low-dose-naltrexone.html' title='MS Patient Blog - On Low Dose Naltrexone (LDN) She Forgets She Has MS'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-2267984259036610650</id><published>2009-07-05T09:53:00.000-07:00</published><updated>2009-07-05T09:54:30.393-07:00</updated><title type='text'>Glutamate and Low Dose Naltrexone (LDN) and MS</title><content type='html'>"Glutamate excess and its reduction by low dose naltrexone (LDN) are the main facets of the hypothesis proposed by the Cornell pathologist Yash Agrawal in explaining the benefits of LDN described in MS (anecdotally and in clinical trials). In his research, Dr. John Hong a senior scientists at the National Institutes of Health, has shown how glutamate contributes to the disease process in Parkinson’s Disease. In his preliminary studies of low dose opiate antagonists such as naltrexone, Dr. Hong has also shown how these compounds reduce glutamate accumulations and stop disease progression in neurological disorders."&lt;br /&gt;&lt;br /&gt;&lt;a href="http://autoimmunedisease.suite101.com/article.cfm/glutamate_excess_in_multiple_sclerosis_variants"&gt;http://autoimmunedisease.suite101.com/article.cfm/glutamate_excess_in_multiple_sclerosis_variants&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-2267984259036610650?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/2267984259036610650/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/glutamate-and-low-dose-naltrexone-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/2267984259036610650'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/2267984259036610650'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/glutamate-and-low-dose-naltrexone-ldn.html' title='Glutamate and Low Dose Naltrexone (LDN) and MS'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5301204177116782403</id><published>2009-07-04T02:03:00.001-07:00</published><updated>2009-07-04T02:03:47.274-07:00</updated><title type='text'>Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: arial, helvetica, sans-serif; font-size: 12px; color: rgb(51, 51, 51); "&gt;&lt;div class="titlegroup" style="margin-bottom: 12pt; "&gt;&lt;div class="title-document" style="display: block; font-size: 17px; font-weight: bold; "&gt;"&lt;span class="Apple-style-span" style="font-size: 12px; font-weight: normal; "&gt;&lt;span class="h5-inline" style="font-style: normal; font-weight: bold; font-size: 1em; display: inline; "&gt;Results. &lt;/span&gt;Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone."&lt;/span&gt;&lt;/div&gt;&lt;div class="title-document" style="display: block; font-size: 17px; font-weight: bold; "&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="title-document" style="display: block; font-size: 17px; font-weight: bold; "&gt;&lt;a href="http://www3.interscience.wiley.com/journal/122350858/abstract?CRETRY=1&amp;amp;SRETRY=0"&gt;http://www3.interscience.wiley.com/journal/122350858/abstract?CRETRY=1&amp;amp;SRETRY=0&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5301204177116782403?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5301204177116782403/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/fibromyalgia-symptoms-are-reduced-by.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5301204177116782403'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5301204177116782403'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/07/fibromyalgia-symptoms-are-reduced-by.html' title='Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4659447677102967334</id><published>2009-06-30T03:30:00.000-07:00</published><updated>2009-06-30T03:31:06.534-07:00</updated><title type='text'>Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015</title><content type='html'>So, no chance at all of the pharmaceutical industry promoting Low Dose Naltrexone (LDN) it would seem.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.prweb.com/releases/2009/06/prweb2528754.htm"&gt;http://www.prweb.com/releases/2009/06/prweb2528754.htm&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4659447677102967334?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4659447677102967334/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/global-autoimmune-disease-therapeutics.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4659447677102967334'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4659447677102967334'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/global-autoimmune-disease-therapeutics.html' title='Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3186961153407299118</id><published>2009-06-25T13:17:00.000-07:00</published><updated>2009-06-25T13:18:04.103-07:00</updated><title type='text'>A Low Dose Naltrexone (LDN) Journal - Advice on Skipping/Double Dosing LDN</title><content type='html'>&lt;div&gt;In short, try not to forget to take LDN and try even harder to not accidentally take 2 doses either.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://ms.about.com/b/2009/06/23/julie-low-dose-naltrexone-journal-dont-double-up-and-dont-skip-doses.htm"&gt;http://ms.about.com/b/2009/06/23/julie-low-dose-naltrexone-journal-dont-double-up-and-dont-skip-doses.htm&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3186961153407299118?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3186961153407299118/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/low-dose-naltrexone-ldn-journal-advice.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3186961153407299118'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3186961153407299118'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/low-dose-naltrexone-ldn-journal-advice.html' title='A Low Dose Naltrexone (LDN) Journal - Advice on Skipping/Double Dosing LDN'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1986817199713327781</id><published>2009-06-20T10:53:00.000-07:00</published><updated>2009-06-20T10:54:45.336-07:00</updated><title type='text'>Immune Response Stimulating Drug Found to Reduce Prostate Tumour Size</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;Preliminary findings show that ' &lt;/span&gt;&lt;span class="Apple-style-span" style="font-family: verdana, fantasy; line-height: 18px; "&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;ipilimumab' shrinks prostrate tumours to operable size.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://news.bbc.co.uk/1/hi/health/8110103.stm"&gt;http://news.bbc.co.uk/1/hi/health/8110103.stm&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1986817199713327781?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1986817199713327781/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/immune-response-stimulating-drug-found.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1986817199713327781'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1986817199713327781'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/immune-response-stimulating-drug-found.html' title='Immune Response Stimulating Drug Found to Reduce Prostate Tumour Size'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4585799923316028716</id><published>2009-06-17T05:59:00.001-07:00</published><updated>2009-06-17T05:59:57.966-07:00</updated><title type='text'>New Yahoo! Group for Low Dose Naltrexone (LDN) Users who Have IBD (Inflammatory Bowel Disease)</title><content type='html'>A new Yahoo! Groups group which is specifically aimed at those who take, or are interested in taking Low Dose Naltrexone (LDN) for IBD (Inflammatory Bowel Disease), e.g. Crohn's Disease and Ulcerative Colitis.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://health.groups.yahoo.com/group/LDNandIBD/"&gt;http://health.groups.yahoo.com/group/LDNandIBD/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4585799923316028716?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4585799923316028716/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/new-yahoo-group-for-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4585799923316028716'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4585799923316028716'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/new-yahoo-group-for-low-dose-naltrexone.html' title='New Yahoo! Group for Low Dose Naltrexone (LDN) Users who Have IBD (Inflammatory Bowel Disease)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5543533394094500753</id><published>2009-06-17T05:51:00.001-07:00</published><updated>2009-07-31T14:42:04.930-07:00</updated><title type='text'>A New Low Dose Naltrexone (LDN) Petition for Australia</title><content type='html'>&lt;a href="http://www.gopetition.com/online/28354.html"&gt;http://www.gopetiti on.com/online/ 28354.html&lt;br /&gt;&lt;/a&gt;&lt;br /&gt;&lt;span style="font-weight: bold;"&gt;National Health Funding for Low Dose Naltrexone in Australia&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Published by Trevor George Stephens&lt;br /&gt;Date: Jun 06, 2009&lt;br /&gt;Category: Health&lt;br /&gt;Region: Australia&lt;br /&gt;Target: Cancer sufferers MS sufferers and HIV+ persons&lt;br /&gt;Web site:&lt;a href="http://www.lowdosenaltrexone.org/"&gt; http://www.lowdosen altrexone. org/&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;Background (Preamble):&lt;br /&gt;&lt;br /&gt;I was diagnosed as being HIV+ in 1987: I participated in the Ozone trial in&lt;br /&gt;the Philippines in 1993 while practicing various alternative and natural&lt;br /&gt;therapies and am 60 years of age in Sept. 2009 and am healthy and well.&lt;br /&gt;&lt;br /&gt;I pursued further Ozone treatment in 1999 in Kenya with the scientist who&lt;br /&gt;developed that particular method of delivery called Polyatomic Apheresis -&lt;br /&gt;The late Basil Wainwright - and returned to Australia early 2000. I&lt;br /&gt;discovered in that year a seeming decrease in my CD4 cells and a&lt;br /&gt;concomitant decrease in my platelets so I went on medication then and&lt;br /&gt;remained fairly steadily on it for some time - four years -with a couple of&lt;br /&gt;intermittent breaks from it due to the development of small lumps in my&lt;br /&gt;sides (abdominal area). In all of this time my cd4's have been only between&lt;br /&gt;200 and 300: however, after being on LDN for some three months - from round&lt;br /&gt;September 2008 - they showed the most significant increase I have seen&lt;br /&gt;since the Ozone trial in 1993.....CD4' s were 350 and CD8's were 1096 with a&lt;br /&gt;non detectable viral load.&lt;br /&gt;&lt;br /&gt;I had a few weeks off around the Christmas and have now passed another&lt;br /&gt;three/four month period taking 4.5 mg every night. My latest results at May&lt;br /&gt;2009 are ... non detectable viral load and CD4 count of 293. The present&lt;br /&gt;cost of this medication at the lower end of the scale is $100+.00 every&lt;br /&gt;three months. I am receipt of a disability pension. I have an interest in&lt;br /&gt;drawing official attention to this medication and having it listed on the&lt;br /&gt;pharmaceutical benefits listings.&lt;br /&gt;&lt;br /&gt;Please send this on to anyone within serious immune boosting concerns /&lt;br /&gt;view the LDN site and sign the petition. Return this petition to me on the&lt;br /&gt;20th January 2010 for review.&lt;br /&gt;&lt;br /&gt;Click 'Tell' to send this petition on and you will assist in maintaining&lt;br /&gt;its momentum and growth.&lt;br /&gt;&lt;br /&gt;Petition:&lt;br /&gt;We petition the Australian government to make funds available for trials&lt;br /&gt;and research for LDN to achieve a licence and public availability. This&lt;br /&gt;medication must be added to the pharmaceuticals benefits listings.&lt;br /&gt;&lt;br /&gt;We petition the Australian government to make funding available, either&lt;br /&gt;directly through taxes or indirectly by directing research bodies to&lt;br /&gt;provide funding, to undergo trials for the generic drug, Low Dose&lt;br /&gt;Naltrexone (LDN).&lt;br /&gt;&lt;br /&gt;Primarily this is to be done for Cancer since there lies the biggest&lt;br /&gt;savings of life and economy, but then also for the many other diseases,&lt;br /&gt;such as MS, Crohns disease, Fibromyalgia, Rheumatoid Arthritis, HIV/Aids&lt;br /&gt;and many more.&lt;br /&gt;&lt;br /&gt;Alternatively, the drug should be made available on the basis of it's&lt;br /&gt;widespread use and the widespread positive reports of the many doctors&lt;br /&gt;around the world who are currently using it. The evidence about this drug&lt;br /&gt;has overtaken the trials process already and as such, we ask also that this&lt;br /&gt;drug be made available as front line treatment, now. The research should&lt;br /&gt;then be performed to confirm the drug and resolve the many unanswered&lt;br /&gt;questions surrounding it.&lt;br /&gt;&lt;br /&gt;To sumarise, we ask for the funding to be provided and the drug to be made&lt;br /&gt;freely available to those who request it. The drug has been proven safe at&lt;br /&gt;high dose usage so the safety trials are done, and we know of no drugs&lt;br /&gt;which become unsafe at low dose when safe at high ones. In 25 years, the&lt;br /&gt;drug industry has ignored this drug due to lack of return on investment, so&lt;br /&gt;we believe that only government led intervention can break this scandalous&lt;br /&gt;apathy. LDN now, save our sick, save our economy.&lt;br /&gt;&lt;br /&gt;Please fund LDN Now!&lt;br /&gt;&lt;br /&gt;To sign the petition:&lt;br /&gt;&lt;a rel="nofollow" target="_blank" href="http://www.gopetiti%20on.com/online/%2028354.html"&gt;http://www.gopetiti on.com/online/ 28354.html&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5543533394094500753?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5543533394094500753/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/new-low-dose-naltrexone-ldn-petition.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5543533394094500753'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5543533394094500753'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/new-low-dose-naltrexone-ldn-petition.html' title='A New Low Dose Naltrexone (LDN) Petition for Australia'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-6061399873208865595</id><published>2009-06-14T12:44:00.000-07:00</published><updated>2009-06-14T12:45:55.992-07:00</updated><title type='text'>Low-Dose Naltrexone for Fibromyalgia &amp; Chronic Fatigue Syndrome</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: Verdana; font-size: 12px; line-height: 18px; "&gt;&lt;h1 style="font-size: 22px; font-style: inherit; font-weight: inherit; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; text-decoration: inherit; color: rgb(62, 62, 62); font: normal normal normal 22px/1.2 Arial; "&gt;&lt;span class="Apple-style-span"    style="font-family:Georgia, fantasy;font-size:130%;color:#000000;"&gt;&lt;span class="Apple-style-span" style="font-size: 16px; line-height: normal;"&gt;&lt;span class="Apple-style-span"    style="font-family:Arial, fantasy;font-size:6;color:#3E3E3E;"&gt;&lt;span class="Apple-style-span" style="font-size: 22px; line-height: 26px;"&gt;"&lt;span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: Verdana, fantasy; font-size: 12px; line-height: 18px; "&gt;An exciting thing about LDN is that it's inexpensive and already on the market. Anecdotal evidence so far is very promising, as is the first clinical trial for FMS.&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande', fantasy; font-size: 14px; line-height: normal; white-space: pre; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px; "&gt;"&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/h1&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"   style="font-family:'Lucida Grande', fantasy;font-size:130%;"&gt;&lt;span class="Apple-style-span" style="font-size: 14px; white-space: pre; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 14px; white-space: pre; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px; "&gt;&lt;a href="http://chronicfatigue.about.com/b/2009/06/13/low-dose-naltrexone-for-fibromyalgia-chronic-fatigue-syndrome.htm"&gt;http://chronicfatigue.about.com/b/2009/06/13/low-dose-naltrexone-for-fibromyalgia-chronic-fatigue-syndrome.htm&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-6061399873208865595?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/6061399873208865595/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/low-dose-naltrexone-for-fibromyalgia.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/6061399873208865595'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/6061399873208865595'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/low-dose-naltrexone-for-fibromyalgia.html' title='Low-Dose Naltrexone for Fibromyalgia &amp; Chronic Fatigue Syndrome'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7128663765844761115</id><published>2009-06-12T13:00:00.000-07:00</published><updated>2009-06-12T13:01:04.056-07:00</updated><title type='text'>Low Dose Naltrexone : The Next Miracle Drug?</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;by &lt;span class="Apple-style-span" style="font-family: Verdana; font-size: 13px; -webkit-border-horizontal-spacing: 3px; -webkit-border-vertical-spacing: 3px; "&gt;Michael D. Shaw, Exec VP, Interscan Corporation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;"L&lt;span class="Apple-style-span" style="font-family: Verdana; font-size: 13px; -webkit-border-horizontal-spacing: 3px; -webkit-border-vertical-spacing: 3px; "&gt;DN is inexpensive with virtually no harmful side effects. However, since it is no longer a proprietary drug, the pace of rolling out clinical trials for the off-label effects described in this article will probably be slow, as will its acceptance by mainstream medicine. Still, there is nothing to prevent a patient from taking an FDA approved drug for an off-label indication, and this practice goes on all the time.&lt;/span&gt;&lt;/div&gt;&lt;span class="Apple-style-span" style="font-family: Verdana; font-size: 13px; -webkit-border-horizontal-spacing: 3px; -webkit-border-vertical-spacing: 3px; "&gt;&lt;br /&gt;Certainly, there is much appeal in a naturally-acting immune modulator that is cheap and effective. We await the publication of further results."&lt;/span&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://www.dentalplans.com/articles/42637/low-dose-naltrexone-the-next-miracle-drug.html"&gt;http://www.dentalplans.com/articles/42637/low-dose-naltrexone-the-next-miracle-drug.html&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7128663765844761115?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7128663765844761115/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/low-dose-naltrexone-next-miracle-drug.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7128663765844761115'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7128663765844761115'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/low-dose-naltrexone-next-miracle-drug.html' title='Low Dose Naltrexone : The Next Miracle Drug?'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7184437302833018371</id><published>2009-06-09T13:46:00.000-07:00</published><updated>2009-06-09T13:53:45.500-07:00</updated><title type='text'>UK Low Dose Naltrexone (LDN) NHS Trial Petition Surpasses 2,500 Signatures</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre; "&gt;The petition on the UK Number 10 Government petition web site to request a Low Dose Naltrexone (LDN) NHS-funded clinical trial&lt;/span&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre; "&gt;has now surpassed 2,500 signatures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;In order to be seriously considered by the UK government, this petition will need to reach 15,000 signatures by 23rd November&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;this year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;If you are a UK citizen, or know one, please spread the word about this important petition.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;If you have already signed it, please pass it on to anyone you know who can sign and please ask them to do the same.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;The election of the BNP to the European Parliament demonstrates, albeit in an unpleasant way, how a small number of people can&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;instigate change - Please use your power to help this petition change the way that Low Dose Naltrexone (LDN) is used in the UK&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;National Health Service and help the millions of people who could benefit from access to this drug move a step closer to the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;opportunity to gain relief from their daily suffering.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;Thank you.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center;"&gt;&lt;a href="http://petitions.number10.gov.uk/LowDNaltrexone/"&gt;http://petitions.number10.gov.uk/LowDNaltrexone/&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7184437302833018371?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7184437302833018371/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/uk-low-dose-naltrexone-ldn-nhs-trial.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7184437302833018371'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7184437302833018371'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/uk-low-dose-naltrexone-ldn-nhs-trial.html' title='UK Low Dose Naltrexone (LDN) NHS Trial Petition Surpasses 2,500 Signatures'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5968477270063753207</id><published>2009-06-04T05:43:00.001-07:00</published><updated>2009-06-04T05:45:46.627-07:00</updated><title type='text'>MS Patient Blog - Improvement Continuing Using Low Dose Naltrexone (LDN)</title><content type='html'>&lt;span class="url fn" style="color: rgb(0, 0, 0);"&gt;Julie  Stachowiak, Ph.D.&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0);"&gt;, writing in her about.com blog - She continues to show improvement in her Multiple Sclerosis symptoms due to treatment with Low Dose Naltrexone (LDN) -&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;a href="http://ms.about.com/b/2009/06/03/julies-low-dose-naltrexone-journal-month-15.htm"&gt;&lt;span style="text-decoration: underline;"&gt;http://ms.about.com/b/2009/06/03/julies-low-dose-naltrexone-journal-month-15.htm&lt;/span&gt;&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5968477270063753207?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5968477270063753207/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/ms-patient-blog-improvement-continuing.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5968477270063753207'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5968477270063753207'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/ms-patient-blog-improvement-continuing.html' title='MS Patient Blog - Improvement Continuing Using Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1197838731207360808</id><published>2009-06-01T06:05:00.000-07:00</published><updated>2009-06-01T06:06:00.051-07:00</updated><title type='text'>Interview with Dr Burton Berkson on Low Dose Naltrexone (LDN) for Cancer Treatment</title><content type='html'>&lt;a href="http://preview.tinyurl.com/pju6mu"&gt;&lt;b&gt;http://preview.tinyurl.com/pju6mu&lt;/b&gt;&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1197838731207360808?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1197838731207360808/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/interview-with-dr-burton-berkson-on-low.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1197838731207360808'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1197838731207360808'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/06/interview-with-dr-burton-berkson-on-low.html' title='Interview with Dr Burton Berkson on Low Dose Naltrexone (LDN) for Cancer Treatment'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-517648236888455650</id><published>2009-05-31T12:27:00.001-07:00</published><updated>2009-05-31T12:27:20.907-07:00</updated><title type='text'>Low Dose Naltrexone (LDN) on twitter</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;Follow Low Dose Naltrexone (LDN) on twitter here -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="color: rgb(84, 84, 84); font-family: 'Lucida Grande'; font-size: 12px; line-height: 16px; "&gt;&lt;a href="http://twitter.com/LD_Naltrexone"&gt;http://twitter.com/LD_Naltrexone&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-517648236888455650?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/517648236888455650/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/low-dose-naltrexone-ldn-on-twitter.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/517648236888455650'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/517648236888455650'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/low-dose-naltrexone-ldn-on-twitter.html' title='Low Dose Naltrexone (LDN) on twitter'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5276349896514677070</id><published>2009-05-30T02:17:00.000-07:00</published><updated>2009-05-30T02:23:45.331-07:00</updated><title type='text'>First European Low Dose Naltrexone (LDN) Conference, Glasgow, Scotland, UK, February 2009</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap; "&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;Below are 4 summary articles I posted on notes I took a the EU LDN Conference.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap; "&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;I've also included the raw notes I took for the whole conference. These are very rough but give a flavour of all of the sessions there and the information therein.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap; "&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap; "&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;Viewing the conference videos is the best way to get the information from the conference -&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap; "&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap;"&gt;&lt;a href="http://glasgowldn2009.com/category/conference-sessions/"&gt;http://glasgowldn2009.com/category/conference-sessions/&lt;br /&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 14px; white-space: pre-wrap; "&gt;&lt;a href="http://www.wearecrohns.org/bobthomson70/journals/2798"&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;http://www.wearecrohns.org/bobthomson70/journals/2798 &lt;/span&gt;&lt;/a&gt;&lt;a href="http://www.wearecrohns.org/bobthomson70/journals/2797"&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;http://www.wearecrohns.org/bobthomson70/journals/2797 &lt;/span&gt;&lt;/a&gt;&lt;a href="http://www.wearecrohns.org/bobthomson70/journals/2795"&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;http://www.wearecrohns.org/bobthomson70/journals/2795 &lt;/span&gt;&lt;/a&gt;&lt;a href="http://www.wearecrohns.org/bobthomson70/journals/2799"&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;http://www.wearecrohns.org/bobthomson70/journals/2799&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;a href="http://www.wearecrohns.org/bobthomson70/journals/2799"&gt;&lt;br /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;NOTE - Below are raw notes, short, and uncorrected for spelling or sense. They are offered as is.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;First  European Conference on LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Glasgow 25th April 2009&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Glasgow University&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Intro&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Linda E..good LDN Research Trust&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MS 20 yrs, LDN 5.5 yrs - apears totally symptom free today.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;V limited mobility, cognitive issues in communicating, severe muscular problems.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dec 2003 started LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dramatic improvement in 3 weeks, fatgue, sight, bladder improved.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Set-up LDN R C as a charity, voluntary work, running costs paid,&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;22K raised towards clinical trial&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Aim - Get LDN on NHS for everyone.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;4200+ registered &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;3000 in UK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;90% have MS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Crohn's ME Parkinson's, Cancer and other conditions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;US and other countries welcome to register&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Current condition - Getting an infection/virus brings up MS symptoms (Some people say they don't get inf/vir on LDN).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dr Bob Lawrence - introduced LDN to UK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dr Tom Gillholly - aiming for trial in UK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDN Research - Dr Tom Gilhooly, Essential Health Clinic, Glasgow&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Published research and science research needed for GPs/ NHS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;1/50th standard dose of 30 yr old drug with good safety record&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Summary of research&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Crohns, Human Study  - Penn State&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;TG 9/10 towards funding for first MS trial in UK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDN - Patent protecton long gone - no pharma studies then.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Uni - Charity funding required&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Hopefully government science funding in UK&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Publication is required (Hence clinical use in clinic not used)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Institutional resistance - Charities are wary of LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Accredited Funding needed - only 1 MS one, not keen on LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;3/4 mg is most research - not ideal - need to educate researchers&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Short duration - 2/4 years needed for LDN, cancer for 5 - therefore more expensive, so need shorte cheaper studies with demonstrable &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Cancer , MS- Ian Zagon - 28 yrs, multiple studies in animals (244 publications)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;1981 - nalexone and cancer in mice&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dr Bihari's became interested, lots of work but unpublished. Work on HIV was refused puiblication&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;IZ - Opiate growth factor increased by LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Seems to naturally inhibits tumour growth in animals&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Experimental Allergic Encephalomyelitis - induced in animals an treated wtih LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MS Society of America has funded research into this which will be published soon&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Sep 2008 Montreal World Congress MS - presented this there&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;High dose naltrexone worsens EAE and makes humans feel worse&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Important to take once per day - short duration &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Human Studies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;FM - Published last week.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;1/4 million FM in UK alone&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Stanford, 10 patient study&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;EHC, using LDN with FM for 6 months, much better than pervious treatment (80% improvement vs 20 with other approaches, nutrition etc)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dosage very dependant. Study used 4.5 for all, TG - mostly 1 - 2 some people have trouble taking more than 1.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;TG's proposed study 120 - largest ever.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Stanford 2010&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Crohn's - most impressive result.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Prof Kill Smith, Penn State U&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;17 patients, 12 wk pilot - 4.5 mg (High) LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Close exam of bowel - 67% remission&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;89% response&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;TG - 3 patients , 2 with servere crohn's - both remission with 1mg quite quickly.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;1 NHS patients with blody d and blood transfusion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;remission for over a year (Stopped LDN as didn't like drugs but maintained remission)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;IBS - Kariv, Tel Aviz  - 47 @ 0.5mg 76% improvement Reduction in pain free days&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;600 patients ouble blind randmoised&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;0..5 mg (Called PTI 901)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;2 momnths mprovement, not after 3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Seems like too low a dose, so IBS not proven really.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Seifrabei et al AJAS 2008&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Haematological  cancers&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;5 mth with 3mg&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Sig imp in qualuty of life at 1 3 and 5 months follow up&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Gironi et al Milan 2008&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Clinical exp LDN is best MS treatment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;40 primary progressive MS (Worst case) - 6 months&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDN safe - only 1 patient progressed&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Significante reduction in spasticity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;No major adverse effects in any study&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Cree et al - Uni Cal SF&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;80 pts 8 week RCT 4.5 mg&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MSQLI - sig imp&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Pain, mental health, cognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Summary&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Numerous publications&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Diverse medical conditions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Seems to be useful for many conditions involving the immune system&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;---&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dickson Chemist &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Home Delivery Pharmacy Services&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;J Stephen Dickson MRPharmS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;0141 647 8032&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Advice came from Pharamcy Prouction Unit at the Western&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;5 medic tyoes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Herbal - low reg&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;GSL - supermarket&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;P - pharmarcy&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;POM - presc only&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;CD - morpheine etc&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MHRA regulated&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MHRA license &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Nalorex (Naltrexone) - Only for treatment of addictiion, 25mg - 200mg&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Therefore, with this use - company is responsible for any ill effects, not Dr or Pharmacist&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;So LDN is&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;POM&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Unlicensed indication an formulation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Responsibility is 50/50 Dr / Pharma&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;NHS will generally not pay (See later)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Legally, any pharmacy can prepare LDN ue to legislation which allows any sensible formulation asked for by Dr.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Sugar free, Vit C preservative, flavouring&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Expiration - legally mandated but vague, therefore 28 days from date on bottle&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Keep in fridge too - minimise bactereological contamination&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Options - vial + syringe, filling tube/adaptor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Unit Dose Vial (UV) - one bottle pre dose - easier for ple with poor dexterity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;3mg and 4.5mg caps&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;'Specials' regulations MHRA importing isssues etc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;v. expensive&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;people buying from US illegally, no Dr involved&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;labelled as 'vitamins' - illegal&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MHRA audited Dickson - non GMP compliance was issue, warning issues and no longer imported from IRMAT.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;No guidance anywhere though.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;May 2009 - 2 suppliers of 30K caps per time, same price as US now&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Invested 60K+ in services&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;now 100+ being invested&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Donating 40p per prescription to fund research from May 2009&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt; &gt; 200 UK Drs will prescribe LDN (30K GPs in UK)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Time of day to take doesn't matter&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Naltrexone will pass on the NFS for payment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Burt -&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Alpha-lipoics accide 600mg 2/week + 4.5mg LDN per day for end stage cancer patients - remission&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Pan can meta liver 2003&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;78 mths later alive and no tumour visible&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Lupus an Arthritis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;v. goo results&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dermatomyositis 20 % de in 1st year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Skin problems barely able to work, severe pain&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;ALAN on other drugs, pain down to 1/5th, 5th of muscle issues - 3 mths later&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;12 mths out - normal&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;200 ;upus patients - great results, test scale figures down to virtually 0 or 0 in 6 months&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Alpha Lipoic acid - a prescription drug in much of EU (In Germant particularly)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;No prescription required in Germany (Anecdotal - Dusseldorf, oriental man)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;ALA affects metabolism, young people have plenty, older people don't.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Need B Vit complex to deal with B Vit depeltion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;PM -&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Saving Lives - One person at a time - Joseph Wouk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;google LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;healthyandessential.com&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDN Research Trust - most recommened web site&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;1 yr LDN - vast improvement. normal&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Yahoo group for LDN&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;6000+ members&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;anecdotal = 'results not a part of an approved double-blind study" != "old wives tale"&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;patientslikeme forum&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt; - backe bt pharma&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;103- mill USD needed for FDA/MHRA appoval&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;re-patent propsal - pragmatic solution, work within current system so drygs can be re-approved for new uses.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Sent to healthreform.gov for Obamha admin.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;attempt to classify as 'Orphan drug' - Dr Gluck, Bihari and Wouk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDNnow.co.uk - website for petition to number 10 for UK trials - 1801 sigs so far.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;The Prompise of Low Dose Naltrexone Therapy : Potential Benefits...&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Elaine A. Moore and Samantha Wilkinson&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;www.googleldn.com&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Reverse SEO? lowdosenaltrexone.org low in results for varous condisions other than LDN itself.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;gets same positon in google as 1/20 of hits site.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Need more links to site from many more web sites - SEO&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;naprotechnology for fertitility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LN helps fertitility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDN used in Ireland since 2004&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;endorphine deficiency a problem with PMS and mis-carriage and fertility&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Study was done on PSM with 25mg a day&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;in Ireland 170 drugs which are prescribed outside of licensing, so what's different about ldn?&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Peer convern amongst doctors?&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;nb 75% of the infliximab patients failed in Penn study who got 66% remission&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;'Yasmin survivors forum' - google this for LDN an mood/PMS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;'Up the Creek wth a Pddle' - Maey Anne Boyle Bradley&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;edometreiosis is 1/2 level of normal fertility on endorphions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;polycystic disease too related to lowendorphon levels&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;persistent brown menstrual bleeding&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;PCOD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;anxiety in ecessiss&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Vit 3 deficiency a problem with fertility as is foo intolerence&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;LDN less effective with sterioud use&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Menopause a big problem with PMS beforehand an low endorphons&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Future for LDN - Tom G&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Gps can prescribe off-license - consultants can't - hence concentrate on GPs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Mechanism - Reuction ion peroxynitrites - ONOOs - damage cell membranes, DNA an denzy,es&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Measure nitrotyrosine - nitrated amino acid&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Damage enzymes which produce energy from nutrition - hence fatigue of many auto immue dieases &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Measurable via LP&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Decreases as immune system becomes reduced and symptoms better&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;First test ever in the world - not validated yet so can't be charged as yet.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&gt; 10 nmol/l bad&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Pre SPMS 8 years = 183 nmol/l&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;1mg 130&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;2mg 108&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;3mg 5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;MS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;CFS/ME?FM&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Psoriasis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;CD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;alopecia&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Endometriosis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Ultricaria&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Cycluc neutropenia&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;SLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Cancer&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Parkinson's&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;JIV&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;ALS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;etc&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;etc&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Dr Ian Zagon coming 2010 conf&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Pharmacist - Skip&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;Vitamin D and Omega 3 are key - don't be defieicnt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica"&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;span class="Apple-style-span"  style="font-family:'times new roman';"&gt;zinc too&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;br /&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;br /&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;br /&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;br /&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;br /&gt;&lt;/p&gt; &lt;p style="margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px Helvetica; min-height: 14.0px"&gt;&lt;br /&gt;&lt;/p&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5276349896514677070?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5276349896514677070/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/first-european-low-dose-naltrexone-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5276349896514677070'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5276349896514677070'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/first-european-low-dose-naltrexone-ldn.html' title='First European Low Dose Naltrexone (LDN) Conference, Glasgow, Scotland, UK, February 2009'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1497849324453626368</id><published>2009-05-30T02:03:00.000-07:00</published><updated>2009-05-30T02:04:37.871-07:00</updated><title type='text'>Scientific Paper on Low Dose Naltrexone (LDN) for Cancer</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;This is by Dr Berkson, who has been having a lot of success with LDN and Alpha Lipoic Acid (ALA) in treating cancer patients.&lt;div&gt;He gave a very interesting presentation at the first European LDN Conference in Glasgow earlier this year. You can see that presentation, and the others from the conference here -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://glasgowldn2009.com/category/conference-sessions/"&gt;http://glasgowldn2009.com/category/conference-sessions/&lt;br /&gt;&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;And the paper is here -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://www.ldn4cancer.com/techpapers/berkson-b-cell-lymphoma-paper.pdf"&gt;http://www.ldn4cancer.com/techpapers/berkson-b-cell-lymphoma-paper.pdf&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1497849324453626368?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1497849324453626368/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/scientific-paper-on-low-dose-naltrexone.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1497849324453626368'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1497849324453626368'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/scientific-paper-on-low-dose-naltrexone.html' title='Scientific Paper on Low Dose Naltrexone (LDN) for Cancer'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1630860869820550087</id><published>2009-05-20T07:19:00.000-07:00</published><updated>2009-05-20T07:21:08.891-07:00</updated><title type='text'>Joseph Wouk's Google LDN!  Book Now on Amazon</title><content type='html'>(Not yet UK unfortunately but it's a start)&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.amazon.com/Google-LDN-Joseph-Wouk/dp/0578004399/ref=sr_1_1?ie=UTF8&amp;amp;s=books&amp;amp;qid=1242403678&amp;amp;sr=8-1"&gt;http://www.amazon.com/Google-LDN-Joseph-Wouk/dp/0578004399/ref=sr_1_1?ie=UTF8&amp;amp;s=books&amp;amp;qid=1242403678&amp;amp;sr=8-1&lt;/a&gt;&lt;br /&gt;&lt;br /&gt;NB. The book is available to read for free on Joseph's web site :&lt;br /&gt;&lt;br /&gt;&lt;a href="http://sclerotics.wordpress.com/"&gt;http://sclerotics.wordpress.com/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1630860869820550087?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1630860869820550087/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/joseph-wouks-google-ldn-book-now-on.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1630860869820550087'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1630860869820550087'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/joseph-wouks-google-ldn-book-now-on.html' title='Joseph Wouk&apos;s Google LDN!  Book Now on Amazon'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-8664993596041304705</id><published>2009-05-18T03:07:00.001-07:00</published><updated>2009-05-18T03:07:28.877-07:00</updated><title type='text'>Low Dose Naltrexone (LDN) Patient Success Stories</title><content type='html'>From the same site as the last post.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.whitakerwellness.com/our-therapies/low-dose-naltrexone-testimonials/"&gt;http://www.whitakerwellness.com/our-therapies/low-dose-naltrexone-testimonials/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-8664993596041304705?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/8664993596041304705/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/low-dose-naltrexone-ldn-patient-success.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8664993596041304705'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/8664993596041304705'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/low-dose-naltrexone-ldn-patient-success.html' title='Low Dose Naltrexone (LDN) Patient Success Stories'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1163601900133094116</id><published>2009-05-18T03:00:00.000-07:00</published><updated>2009-05-18T03:07:42.477-07:00</updated><title type='text'>Another Low Dose Naltrexone (LDN) Intro</title><content type='html'>Another nice, brief summary for beginners / your local doctor who's never head of LDN.&lt;br /&gt;&lt;br /&gt;&lt;a href="http://www.whitakerwellness.com/our-therapies/low-dose-naltrexone-ldn/"&gt;http://www.whitakerwellness.com/our-therapies/low-dose-naltrexone-ldn/&lt;/a&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1163601900133094116?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1163601900133094116/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/another-low-dose-naltrexone-ldn-intro.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1163601900133094116'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1163601900133094116'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/another-low-dose-naltrexone-ldn-intro.html' title='Another Low Dose Naltrexone (LDN) Intro'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4262562260583907142</id><published>2009-05-12T13:10:00.001-07:00</published><updated>2009-05-12T13:10:43.595-07:00</updated><title type='text'>Quick Low Dose Naltrexone (LDN) Summary</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;From the point of view of MS, but a great, succinct summary of LDN -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://www.msrc.co.uk/index.cfm?fuseaction=show&amp;amp;pageid=651"&gt;http://www.msrc.co.uk/index.cfm?fuseaction=show&amp;amp;pageid=651&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4262562260583907142?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4262562260583907142/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/quick-low-dose-naltrexone-ldn-summary.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4262562260583907142'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4262562260583907142'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/quick-low-dose-naltrexone-ldn-summary.html' title='Quick Low Dose Naltrexone (LDN) Summary'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4102930130684772989</id><published>2009-05-12T12:43:00.000-07:00</published><updated>2009-05-12T12:45:26.682-07:00</updated><title type='text'>(From Last Year) MS LDN Patient Takes the Message to CA Governor Schwarzenegger</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; white-space: pre; "&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;An inspiring story.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; font-size: 11px; white-space: pre;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://autoimmunedisease.suite101.com/article.cfm/focus_on_low_dose_naltrexone"&gt;http://autoimmunedisease.suite101.com/article.cfm/focus_on_low_dose_naltrexone&lt;/a&gt;&lt;br /&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4102930130684772989?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4102930130684772989/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/from-last-year-ms-ldn-patient-takes.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4102930130684772989'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4102930130684772989'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/from-last-year-ms-ldn-patient-takes.html' title='(From Last Year) MS LDN Patient Takes the Message to CA Governor Schwarzenegger'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1884404518359136251</id><published>2009-05-10T04:33:00.001-07:00</published><updated>2009-05-10T04:34:46.699-07:00</updated><title type='text'>More 'Advertorial' Fake Medical Journals</title><content type='html'>&lt;span class="Apple-style-span"  style=" ;font-family:Times;"&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;It seems a business called Elsevier published multiple fake, 'advertorial' medical journals now.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://laikaspoetnik.wordpress.com/2009/05/08/mercks-ghostwriters-haunted-papers-and-fake-elsevier-journals/"&gt;Blog on The Case&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;a href="http://www.guardian.co.uk/commentisfree/2009/may/09/bad-science-medical-journals-companies"&gt;Bad Science in The Guardian&lt;/a&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1884404518359136251?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1884404518359136251/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/more-advertorial-fake-medical-journals.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1884404518359136251'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1884404518359136251'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/more-advertorial-fake-medical-journals.html' title='More &apos;Advertorial&apos; Fake Medical Journals'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7143299231994061681</id><published>2009-05-06T07:34:00.000-07:00</published><updated>2009-05-06T07:35:19.329-07:00</updated><title type='text'>Mid-Ulster Group Campaigning for LDN (Low Dose Naltrexone)</title><content type='html'>&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;"&lt;span class="Apple-style-span" style="font-family: Arial; font-size: 12px; "&gt;At present members in Mid-Ulster are campaigning for the government to fund a trial of the drug Low Dose Naltrexone (LDN) on the NHS so that people in the UK can reap the benefits of it - visit the website http://www.ldnnow.co.uk/main.html?src=%2F).&lt;/span&gt;&lt;/div&gt;&lt;span class="Apple-style-span" style="font-family: Arial; font-size: 12px; "&gt;&lt;br /&gt;ITV show This Morning featured a talk on Multiple Sclerosis and LDN as part of MS Awareness week.&lt;br /&gt;&lt;br /&gt;Dr Tom Gilhooly, the Scottish doctor who is a strong advocate for using LDN to help treat MS was interviewed.&lt;br /&gt;&lt;br /&gt;Dr Gilhooly also talked about MSRC's bi-monthly publication 'New Pathways Magazine', which, for MS Awareness Week is being offered free for a year to new subscribers, in the UK. To get your free subscription, please telephone 01206 505444 or email info@msrc.co.uk. "&lt;/span&gt;&lt;div&gt;&lt;span class="Apple-style-span"   style="font-family:Arial;font-size:100%;"&gt;&lt;span class="Apple-style-span" style="font-size: 12px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"   style="font-family:Arial;font-size:100%;"&gt;&lt;span class="Apple-style-span" style="font-size: 12px;"&gt;&lt;a href="http://www.midulstermail.co.uk/news/MidUlster-group-making-a-noise.5238476.jp"&gt;http://www.midulstermail.co.uk/news/MidUlster-group-making-a-noise.5238476.jp&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"   style="font-family:Arial;font-size:100%;"&gt;&lt;span class="Apple-style-span" style="font-size: 12px; "&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7143299231994061681?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7143299231994061681/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/mid-ulster-group-campaigning-for-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7143299231994061681'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7143299231994061681'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/mid-ulster-group-campaigning-for-ldn.html' title='Mid-Ulster Group Campaigning for LDN (Low Dose Naltrexone)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7035575283376838833</id><published>2009-05-03T11:59:00.001-07:00</published><updated>2009-05-03T11:59:48.277-07:00</updated><title type='text'>Pharmaceutical Company Merck Created a Fake Journal</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: medium; "&gt;The Scientist reports that Merck invented a fake peer-reviewed journal called, 'The &lt;/span&gt;&lt;span class="Apple-style-span" style="font-family: Verdana; line-height: 18px; "&gt;&lt;span class="Apple-style-span" style="font-size: medium; "&gt;Australasian Journal of Bone and Joint Medicine' in which it published papers with favourable looking data on Merck products.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://blog.bioethics.net/2009/05/merck-makes-phony-peerreview-journal/"&gt;http://blog.bioethics.net/2009/05/merck-makes-phony-peerreview-journal/&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7035575283376838833?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7035575283376838833/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/pharmaceutical-company-merck-created.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7035575283376838833'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7035575283376838833'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/pharmaceutical-company-merck-created.html' title='Pharmaceutical Company Merck Created a Fake Journal'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3882961257310420180</id><published>2009-05-01T06:35:00.001-07:00</published><updated>2009-05-01T06:36:22.045-07:00</updated><title type='text'>European Low Dose Naltrexone (LDN) Conference, Glasgow 2009 - Videos</title><content type='html'>&lt;div&gt;Video of the presentations given last Saturday at the first European LDN Conference is now availble online here -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://glasgowldn2009.com/category/conference-sessions/"&gt;http://glasgowldn2009.com/category/conference-sessions/&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3882961257310420180?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3882961257310420180/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/european-low-dose-naltrexone-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3882961257310420180'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3882961257310420180'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/05/european-low-dose-naltrexone-ldn.html' title='European Low Dose Naltrexone (LDN) Conference, Glasgow 2009 - Videos'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3792939854666840207</id><published>2009-04-30T05:54:00.001-07:00</published><updated>2009-04-30T06:02:44.733-07:00</updated><title type='text'>Tips for Those New to Low Dose Naltrexone (LDN)</title><content type='html'>&lt;span class="Apple-style-span"  style=" ;font-family:Times;"&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;(c/o A. Hansen, &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;&lt;a href="http://health.groups.yahoo.com/group/lowdosenaltrexone/"&gt;Yahoo! Low Dose Naltrexone Group&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:small;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style=" line-height: 15px; "&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;Why you may get increased symptoms in 1st 3 months on LDN, by Dr. Bob Lawrence - &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://preview. tinyurl.com/ ca2flq"&gt;http://preview. tinyurl.com/ ca2flq&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;br /&gt;Why some May have problems with or fail LDN - &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://preview.tinyurl.com/dfv5ou"&gt;http://preview. tinyurl.com/ dfv5ou&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;br /&gt;For those having trouble w/LDN no longer working  - &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://preview.tinyurl.com/chajp3"&gt;http://preview. tinyurl.com/ chajp3&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;br /&gt;Check yourself for &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://en.wikipedia.org/wiki/Candida"&gt;Candida&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt; (Yeast overgrowth) - &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://preview.tinyurl.com/c9eyzx"&gt;http://preview. tinyurl.com/ c9eyzx&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;br /&gt;&lt;br /&gt;Tests to check for &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://en.wikipedia.org/wiki/Candida"&gt;Candida&lt;/a&gt;&lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt; yeast by Dr. McCandless - &lt;/span&gt;&lt;span class="Apple-style-span"  style="font-size:medium;"&gt;&lt;a href="http://preview.tinyurl.com/cxp6bx"&gt;http://preview. tinyurl.com/ cxp6bx&lt;/a&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3792939854666840207?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3792939854666840207/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/tips-for-those-new-to-low-dose.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3792939854666840207'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3792939854666840207'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/tips-for-those-new-to-low-dose.html' title='Tips for Those New to Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3246698164721429675</id><published>2009-04-29T14:55:00.000-07:00</published><updated>2009-04-29T14:56:18.797-07:00</updated><title type='text'>Low Dose Naltrexone (LDN) Prescription Guidelines for Doctors</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;"&lt;/div&gt;&lt;span class="Apple-style-span" style="font-family: Arial; color: rgb(0, 51, 51); font-size: 12px; "&gt;&lt;table width="100%" border="0" cellspacing="0" cellpadding="4" summary="Table containing page heading"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td class="head1" style="font-family: Arial, Helvetica, sans-serif; font-size: large; font-weight: bold; "&gt;Prescribing Low Dose Naltrexone – A Guide&lt;/td&gt;&lt;td valign="middle" align="right" style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; "&gt;&lt;b&gt;&lt;br /&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table width="100%" border="0" cellspacing="0" cellpadding="4" summary="table containing main page content"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="font-family: Arial, Helvetica, sans-serif; font-size: 12px; "&gt;&lt;p&gt;Prescribing Low Dose Naltrexone – A Guide&lt;/p&gt;&lt;p&gt;Dr Tom Gilhooly Essential Health Clinic   Glasgow"&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/span&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://www.msrc.co.uk/index.cfm?fuseaction=show&amp;amp;pageid=2859"&gt;http://www.msrc.co.uk/index.cfm?fuseaction=show&amp;amp;pageid=2859&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3246698164721429675?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3246698164721429675/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/low-dose-naltrexone-ldn-prescription.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3246698164721429675'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3246698164721429675'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/low-dose-naltrexone-ldn-prescription.html' title='Low Dose Naltrexone (LDN) Prescription Guidelines for Doctors'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-3003897598699895953</id><published>2009-04-29T03:27:00.000-07:00</published><updated>2009-04-29T03:31:08.321-07:00</updated><title type='text'>You and Yours, BBC Radio 4</title><content type='html'>An email was sent to You and Yours, BBC Radio 4 to suggest a programme on Low Dose Naltrexone (LDN).  The response is below.&lt;div&gt;If you would like to contact the programme to suggest an item on LDN, please do so by following the link -&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: 13px; line-height: 15px; "&gt;&lt;a href="http://www.bbc. co.uk/radio4/ youandyours/ youandyours_ contact.shtml" style="text-decoration: none;"&gt;http://www.bbc. co.uk/radio4/ youandyours/ youandyours_ contact.shtml&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: 13px; line-height: 15px; "&gt;"Dear Bob,&lt;br /&gt; &lt;br /&gt;Many thanks for your message.&lt;br /&gt; &lt;br /&gt;We are aware of LDN and may consider doing a piece on it at&lt;br /&gt;some point. I would therefore like to keep your details if&lt;br /&gt;we need to contact you in the future. &lt;br /&gt;Thank you again for contacting You and Yours.&lt;br /&gt; &lt;br /&gt; &lt;br /&gt;Best wishes,&lt;br /&gt;Carolyn Atkinson.&lt;br /&gt;You and Yours"&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-3003897598699895953?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/3003897598699895953/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/you-and-yours-bbc-radio-4.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3003897598699895953'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/3003897598699895953'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/you-and-yours-bbc-radio-4.html' title='You and Yours, BBC Radio 4'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5540356455065554742</id><published>2009-04-29T02:14:00.000-07:00</published><updated>2009-04-29T02:15:43.810-07:00</updated><title type='text'>ITV This Morning Item on LDN</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;p style="margin: 0.0px 0.0px 15.0px 0.0px; font: 13.0px Arial"&gt;Dr Tom Gilhooley is an expert on MS and a keen advocate of a revolutionary new treatment, LDN.&lt;br /&gt;&lt;br /&gt;"This is a cheap drug and has been proved to be safe and, in my experience, very effective in treating MS. Any GP can prescribe it to patients with MS now if they wanted to, and patients can ask for it, but there's no guarantee that their GPs will want to give them it without a trial to prove its effectiveness."&lt;br /&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;a href="http://www.itv.com/Lifestyle/ThisMorning/Health/MultipleSclerosis123/default.html"&gt;http://www.itv.com/Lifestyle/ThisMorning/Health/MultipleSclerosis123/default.html&lt;/a&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5540356455065554742?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5540356455065554742/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/itv-this-morning-item-on-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5540356455065554742'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5540356455065554742'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/itv-this-morning-item-on-ldn.html' title='ITV This Morning Item on LDN'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1241162484372995285</id><published>2009-04-29T00:46:00.000-07:00</published><updated>2009-04-29T00:49:09.375-07:00</updated><title type='text'>Video Interviews from EU Low Dose Naltrexone (LDN) Conference, Glasgow 2009</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="line-height: 16px; "&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;Video interviews with various presenters, doctors and patients who were at the European Low Dose Naltrexone Conference in Glasgow, Scotland in April 2009.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"    style="font-family:'Lucida Grande';font-size:100%;color:#545454;"&gt;&lt;span class="Apple-style-span" style="font-size: 12px; line-height: 16px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://glasgowldn2009.com/category/conference-video-interviews/"&gt;http://glasgowldn2009.com/category/conference-video-interviews/&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1241162484372995285?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1241162484372995285/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/video-interviews-from-eu-low-dose.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1241162484372995285'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1241162484372995285'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/video-interviews-from-eu-low-dose.html' title='Video Interviews from EU Low Dose Naltrexone (LDN) Conference, Glasgow 2009'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4962816365378006835</id><published>2009-04-29T00:42:00.001-07:00</published><updated>2009-04-29T00:42:45.033-07:00</updated><title type='text'>Pre-registration for EU LDN Conference 2010 Available Now</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; color: rgb(119, 119, 119); font-size: 12px; line-height: 16px; "&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; "&gt;You can now pre-register to attend the European Low Dose Nalrtrexone (LDN) Conference in Glasgow, Scotland, UK on Friday 23rd and Saturday 24th (Open to public on Saturday, clinicians only on Friday).&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; "&gt;http://glasgowldn2009.com&lt;/p&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4962816365378006835?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4962816365378006835/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/pre-registration-for-eu-ldn-conference.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4962816365378006835'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4962816365378006835'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/pre-registration-for-eu-ldn-conference.html' title='Pre-registration for EU LDN Conference 2010 Available Now'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-23920821479836880</id><published>2009-04-29T00:33:00.000-07:00</published><updated>2009-04-29T00:35:56.629-07:00</updated><title type='text'>Dr Tom Gilhooly on ITV This Morning Programme 10:30 Wed 29th April 2009</title><content type='html'>&lt;div&gt;Dr Tom Gilhooly is appearing with TV doctor, Dr. Chris Steele on ITV's This Morning programme at 10:30 today, Wednesday 29th April 2009.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;Video link will be posted here when it's available.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;This is a great opportunity to tell 100's of thousands of viewers about Low Dose Naltrexone (LDN).&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-23920821479836880?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/23920821479836880/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/dr-tom-gilhooly-on-itv-this-morning.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/23920821479836880'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/23920821479836880'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/dr-tom-gilhooly-on-itv-this-morning.html' title='Dr Tom Gilhooly on ITV This Morning Programme 10:30 Wed 29th April 2009'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5005193205119568536</id><published>2009-04-28T11:41:00.001-07:00</published><updated>2009-04-28T11:41:29.569-07:00</updated><title type='text'>A Case of Remission from Crohn's Disease  with Low Dose Naltrexone LDN</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: Verdana; color: rgb(51, 0, 102); font-size: 18px; font-weight: bold; -webkit-border-horizontal-spacing: 5px; -webkit-border-vertical-spacing: 5px; "&gt;A Case of Remission from Crohn's Disease&lt;br /&gt;with Low Dose Naltrexone LDN &lt;span class="Apple-style-span" style="font-size: 13px; font-weight: normal; "&gt;by Jeffrey Dach MD&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://jeffreydach.com/2009/01/12/crohns-recovery-with-low-dose-naltrexone-ldn-by-jeffrey-dach-md.aspx?ref=rss"&gt;Dr Dach's Report&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5005193205119568536?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5005193205119568536/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/case-of-remission-from-crohns-disease.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5005193205119568536'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5005193205119568536'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/case-of-remission-from-crohns-disease.html' title='A Case of Remission from Crohn&apos;s Disease  with Low Dose Naltrexone LDN'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7880728632296753279</id><published>2009-04-28T11:17:00.001-07:00</published><updated>2009-04-28T11:18:54.244-07:00</updated><title type='text'>Chronic Fatigue Sufferer Benefits from LDN</title><content type='html'>&lt;div&gt;"&lt;span class="Apple-style-span" style="font-family: Arial; color: rgb(51, 51, 51); font-size: 12px; "&gt;"Chronic fatigue syndrome drags you down," she said. "I'm now able to do things again. LDN has had a positive effect on me.""&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span"    style="font-family:Arial;font-size:100%;color:#333333;"&gt;&lt;span class="Apple-style-span" style="font-size: 12px;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://www.theherald.co.uk/news/news/display.var.2504159.0.Lifechanging_benefits_for_patients_using_addiction_drug.php"&gt;The Herald article&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7880728632296753279?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7880728632296753279/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/chronic-fatigue-sufferer-benefits-from.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7880728632296753279'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7880728632296753279'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/chronic-fatigue-sufferer-benefits-from.html' title='Chronic Fatigue Sufferer Benefits from LDN'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-5993041973414194168</id><published>2009-04-28T06:43:00.000-07:00</published><updated>2009-04-28T06:45:01.452-07:00</updated><title type='text'>ldn-help.com Coverage of European LDN Conference</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span"   style="font-family:'Lucida Grande';font-size:100%;"&gt;&lt;span class="Apple-style-span"  style=" white-space: pre;font-size:11px;"&gt;&lt;span class="Apple-style-span"   style="font-family:Georgia;font-size:130%;"&gt;&lt;span class="Apple-style-span"  style=" white-space: normal;font-size:16px;"&gt;&lt;span class="Apple-style-span"  style="color: rgb(51, 51, 51);  font-size:13px;"&gt;&lt;div class="post-body entry-content" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.75em; margin-left: 0px; line-height: 1.6em; "&gt;&lt;div&gt;&lt;span class="Apple-style-span"  style=" ;font-family:Times;"&gt;&lt;div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 4px; padding-right: 6px; padding-bottom: 4px; padding-left: 6px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: white; line-height: 1.4em; font-family: 'Lucida Grande', Arial, Helvetica, Verdana, sans-serif; color: rgb(84, 84, 84); "&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; "&gt;Coverage including Mary Boyle's Bradley's radio show.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; "&gt;(Mary Boyle Bradley wrote a book on her experience with MS and LDN : &lt;a href="http://www.amazon.co.uk/Creek-Paddle-Autoimmune-Disorders-Naltrexone/dp/1432711504/ref=sr_1_1?ie=UTF8&amp;amp;s=books&amp;amp;qid=1240926083&amp;amp;sr=8-1" style="color: rgb(153, 153, 153); text-decoration: none; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; "&gt;Up the Creek with a Paddle, Beat MS and All Autoimmune Disorders with Low Dose Naltrexone (LDN)&lt;/a&gt; )&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 1em; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; "&gt;&lt;a href="http://www.ldn-help.com/glasgow2009.html"&gt;http://www.ldn-help.com/glasgow2009.html&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-5993041973414194168?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/5993041973414194168/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ldn-helpcom-coverage-of-european-ldn.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5993041973414194168'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/5993041973414194168'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ldn-helpcom-coverage-of-european-ldn.html' title='ldn-help.com Coverage of European LDN Conference'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7964176281570573691</id><published>2009-04-28T02:43:00.001-07:00</published><updated>2009-04-28T02:44:24.766-07:00</updated><title type='text'>40 Year MS Patient Says LDN Works</title><content type='html'>&lt;div&gt;&lt;b&gt;40 Year MS Patient Says LDN Works&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;"G&lt;span class="Apple-style-span" style="font-family: Arial; font-size: 13px; line-height: 16px; "&gt;oldberg, who lives in Totteridge, North London, also tells me that he has just started to take low-dose Naltrexone, a drug used to treat addictions, which is gaining credibility as a treatment for MS. Its use in this context is not licenced in the UK and is supported only by small pilot clinical trials. “I know it works because I'm using it,” he says. “You could say it's a calculated experiment.”"&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://www.timesonline.co.uk/tol/life_and_style/health/article6031620.ece"&gt;Times Online Article&lt;/a&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7964176281570573691?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7964176281570573691/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/40-year-ms-patient-says-ldn-works.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7964176281570573691'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7964176281570573691'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/40-year-ms-patient-says-ldn-works.html' title='40 Year MS Patient Says LDN Works'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-4481411415579329360</id><published>2009-04-28T02:37:00.000-07:00</published><updated>2009-04-28T02:38:11.787-07:00</updated><title type='text'>MS Patient's Journal on Her Experience with Low Dose Naltrexone (LDN)</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;div&gt;&lt;b&gt;MS Patient's Journal on Her Experience with Low Dose Naltrexone (LDN)&lt;/b&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="color: rgb(77, 74, 66); font-size: 11px; line-height: 18px; "&gt;&lt;a class="url fn" href="http://ms.about.com/mbiopage.htm" style="font-size: 11px; font-style: inherit; font-weight: bold; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; text-decoration: none; color: rgb(51, 102, 204); "&gt;Julie Stachowiak, Ph.D.&lt;/a&gt;, writes in about.com of her experience using Low Dose Naltrexone (LDN) to treat her Multiple Sclerosis (MS)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://ms.about.com/b/2009/04/21/julies-low-dose-naltrexone-journal-preparation.htm"&gt;Julie's journal.&lt;/a&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-4481411415579329360?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/4481411415579329360/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ms-patients-journal-on-her-experience.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4481411415579329360'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/4481411415579329360'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ms-patients-journal-on-her-experience.html' title='MS Patient&apos;s Journal on Her Experience with Low Dose Naltrexone (LDN)'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-256772063915513932</id><published>2009-04-26T14:55:00.000-07:00</published><updated>2009-04-26T14:56:39.741-07:00</updated><title type='text'>LDN and Fibromyalgia</title><content type='html'>&lt;span class="Apple-style-span" style="color: rgb(51, 51, 51); font-size: 13px; "&gt;&lt;h3 class="post-title entry-title" style="margin-top: 0.25em; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 4px; padding-left: 0px; font-size: 18px; font-weight: normal; line-height: 1.4em; color: rgb(204, 102, 0); "&gt;&lt;span class="Apple-style-span" style="color: rgb(51, 51, 51); font-size: 13px; line-height: 20px; font-weight: bold; "&gt;LDN Helps Ease Symptoms of Fibromyalgia in Stanford U Pilot&lt;/span&gt;&lt;/h3&gt;&lt;div class="post-body entry-content" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0.75em; margin-left: 0px; line-height: 1.6em; "&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://insciences.org/article.php?article_id=4389"&gt;Article&lt;/a&gt; - insciences.org web site.&lt;/div&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-256772063915513932?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/256772063915513932/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ldn-and-fibromyalgia.html#comment-form' title='1 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/256772063915513932'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/256772063915513932'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ldn-and-fibromyalgia.html' title='LDN and Fibromyalgia'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7601300591634151004</id><published>2009-04-26T13:38:00.000-07:00</published><updated>2009-04-26T13:41:09.198-07:00</updated><title type='text'>European LDN Conference 2009, Glasgow - Joseph Wouk's Presentation</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span"  style="font-family:'Lucida Grande';"&gt;&lt;span class="Apple-style-span" style="line-height: 16px; "&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;&lt;b&gt;European LDN Conference 2009, Glasgow - Joseph Wouk's Talk on LDN&lt;/b&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;&lt;br /&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-size: medium;"&gt;Joseph Wouk suffers from, or should I say, used to suffer from progressive, relapsing multiple sclerosis. Here he talks about his experiences with MS and his subsequent treatment and vast improvement on Low Dose Naltrexone (LDN)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; color: rgb(119, 119, 119); font-size: 12px; line-height: 16px; "&gt;&lt;a href="http://www.viddler.com/explore/josephwouk/videos/1/"&gt;Video&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7601300591634151004?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7601300591634151004/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/european-ldn-conference-2009-glasgow_26.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7601300591634151004'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7601300591634151004'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/european-ldn-conference-2009-glasgow_26.html' title='European LDN Conference 2009, Glasgow - Joseph Wouk&apos;s Presentation'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-2640514195214389494</id><published>2009-04-26T11:41:00.000-07:00</published><updated>2009-04-26T11:44:10.515-07:00</updated><title type='text'>European LDN Conference 2009, Glasgow, LDN Research Summary - Dr Tom Gilhooly, Essential Health Clinic, Glasgow</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 4px; padding-right: 6px; padding-bottom: 4px; padding-left: 6px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: white; line-height: 1.4em; font-family: 'Lucida Grande', Arial, Helvetica, Verdana, sans-serif; color: rgb(84, 84, 84); background-position: initial initial; "&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;span class="Apple-style-span" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 18px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; color: rgb(0, 0, 0); font-family: 'Lucida Grande'; white-space: pre; background-position: initial initial; "&gt;&lt;span class="Apple-style-span" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 18px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font-weight: bold; background-position: initial initial; "&gt;European LDN Conference 2009, Glasgow&lt;/span&gt;&lt;/span&gt;&lt;span class="Apple-style-span" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font-weight: bold; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;span class="Apple-style-span" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font-weight: bold; background-position: initial initial; "&gt;LDN Research Summary - Dr Tom Gilhooly, &lt;a href="http://essentialhealthclinic.com"&gt;Essential Health Clinic, Glasgow&lt;/a&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Although Low Dose Naltrexone (LDN) is just 1/50th of the standard dose of Naltrexone, a 30 year old drug with a good safety record, published research and science research is needed in order for UK NHS GPs and NHS clinicials in general to feel comfortable with prescribing LDN.&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Summary of research -&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Initial notable research - Penn State - A human study on Crohn's Disease patients showed great results. NOTE - With much larger doses than Dr T G is using.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Today - Dr Tom Gilhooly says we are  9 10ths of the way towards funding for the first trial in UK using LDN on Multiple Sclerosis (MS) patients (120 patients).&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;The patent protection for Naltrexone is long gone - So, it is unlikely there will be any studies carried out by any pharmaceutical company.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Therefore, University or - Charity funding is required&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Hopefully government science funding in the UK will be available.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Again - Publication is required (Hence clinical use in Dr T G's clinic has not been written up - Not seen as relevant by most professionals)&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Issue : Institutional resistance - Charities are wary of LDN&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Accredited Funding needed - There is only 1 such MS charity, but they are not keen on LDN&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Most research has concentrate on relatively large doses of 3 - 4 mg - Dr T G's clinic stat on 1mg and work up to optimum dose which is often not much more than 1 or even use 1mg  -Therefore there is a need to educate researchers on dosage.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Short duration studies - 2 - 4 years needed for LDN. For use in cancer,  5 years - therefore more longer studies are more expensive, so need shorter cheaper studies with demonstrable results.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;LDN in Cancer , MS - Dr Ian Zagon - Has been publishing results for 28 yrs. Has done multiple studies in animals (244 publications)&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;First in 1981 - Nalexone and cancer in mice.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Subsequently Dr Bernard Bihari became interested. He did lots of work but often unpublished. His work on HIV was refused publication by many journals so went unpublished.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Dr Ian Zagon - Found that opiate growth factor was increased by LDN and this seemed to naturally inhibit tumour growth in animals.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Used Experimental Allergic Encephalomyelitis (EAE) - This was induced in animals and treated wtih LDN&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;MS Society of America has funded research into this which will be published soon.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Dr I Z's MS study was presented at the September 2008 Montreal World Congress on MS.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Finding - High dose Naltrexone worsens EAE and makes humans feel worse.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Therefore, low dosages required and it is important to take once per day - So the effect us for a short duration.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Human Studies :&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Fibromyalgia (FM) - Paper published last week.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;There are 250,000 FM sufferers in the UK alone&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Stanford - 10 FM patient study due to report in 2010.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Dr T G - Essential Health Clinic, Glasgow - Clinical findings -&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Have been using LDN with FM for 6 months, much better than previous treatment  - 80% improvement vs 20% with other approaches, e.g. Nutrition, lifestyle improvement.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Effect is very dosage dependant.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;All studies used 4.5mg, TG - mostly 1 - 2 some people have trouble taking more than 1.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Penn State, Crohn's - Still the most impressive result.&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Done by Professor Jill Smith, Penn State University.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;17 patients over 12 weeks pilot study- Used 4.5 mg LDN (Again, note this is high compared with Dr T G's clinical experience).&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Very rigourous - Close examination of colon.&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Findings -&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;67% of patients went into remission.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;89% responded positively in some way.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Dr T G's, EHC clinical findings - 3 patients , 2 with severe Crohn's - both entered remission with 1mg quite quickly. (NOTE - I am the 4th patient but I'm new! LOL)&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;One of Dr T G's NHS patients had bloody &lt;span class="Apple-style-span" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 11px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; color: rgb(0, 0, 0); font-family: 'Lucida Grande'; border-collapse: collapse; white-space: pre; -webkit-border-horizontal-spacing: 2px; -webkit-border-vertical-spacing: 2px; background-position: initial initial; "&gt;diarrhea&lt;span class="Apple-style-span" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; border-collapse: separate; font-family: Helvetica; white-space: normal; -webkit-border-horizontal-spacing: 0px; -webkit-border-vertical-spacing: 0px; color: rgb(84, 84, 84); background-position: initial initial; "&gt; so severe they had to have a blood transfusion. This patient is now in remission for over a year. The patient has actually stopped LDN as they didn't like to take drugs (!) but has maintained remission.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;IBS Study- Kariv et al, Tel Aviv  - 47 patients with 0.5mg (Very low dose) - Saw 76% improvement and increase in reduction in pain-free days.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Another study - 600 patients double-blind, randomised -&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;0.5 mg (Called PTI 901)&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;2 months of improvement, but no further improvement after 3 months.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Seems like too low a dose, so IBS not proven really.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Seifrabei et al AJAS 2008 - Study on Haematological  cancers&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;5 months treatment with 3mg&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Significant improvement in quality of life measurements at 1, 3 and 5 months follow up.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;MS Study - Gironi et al Milan 2008&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Dr T G's EHC Clinical experience -  LDN is the best MS treatment.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Treated 40 primary progressive MS patients (Worst case scenario) over 6 months&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Only 1 patient out of the 40 experienced any progression in their symptoms.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;There was a significant reduction in spasticity found.&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Cree et al - University of California at  San Francisco&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;80 patients for 8 weeks, randomised controller trial using 4.5 mg&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Significant improvement using MS Quality of Life Index.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Pain, mental health and cognition all improved significantly.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;NOTE - Side Effects - No major adverse effects have been found in any of the studies done so far anywhere.&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;Therefore - There is no risk in prescribing LDN.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;In Summary :&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;There have been numerous publications of results of using LDN.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;LDN has been tested in use for a diverse range of medical conditions&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;LDN Seems to be useful for many conditions involving the immune system&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;Further Reading :&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;a href="http://www.lowdosenaltrexone.org/bbihari_cv.htm"&gt;Dr Bihari&lt;/a&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; background-position: initial initial; "&gt;&lt;a href="http://fred.psu.edu/ds/retrieve/fred/investigator/isz1"&gt;Dr Ian Zagon&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-2640514195214389494?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/2640514195214389494/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/european-ldn-conference-2009-glasgow.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/2640514195214389494'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/2640514195214389494'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/european-ldn-conference-2009-glasgow.html' title='European LDN Conference 2009, Glasgow, LDN Research Summary - Dr Tom Gilhooly, Essential Health Clinic, Glasgow'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-1787756218509608688</id><published>2009-04-26T11:04:00.001-07:00</published><updated>2009-04-26T11:05:09.397-07:00</updated><title type='text'>LDN A Personal Experience - Linda Elsegood of The LDN Research Trust, European LDN Conference 2009, Glasgow.</title><content type='html'>&lt;span class="Apple-style-span" style="font-family: Times; "&gt;&lt;div style="border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 3px; padding-right: 3px; padding-bottom: 3px; padding-left: 3px; width: auto; font: normal normal normal 100%/normal Georgia, serif; text-align: left; "&gt;&lt;span class="Apple-style-span"  style="font-family:Times;"&gt;&lt;div style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 4px; padding-right: 6px; padding-bottom: 4px; padding-left: 6px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: white; line-height: 1.4em; font-family: 'Lucida Grande', Arial, Helvetica, Verdana, sans-serif; color: rgb(84, 84, 84); "&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;span class="Apple-style-span" style="color: rgb(0, 0, 0); font-family: 'Lucida Grande'; font-size: 11px; white-space: pre; "&gt;&lt;b&gt;LDN A Personal Experience - Linda Elsegood of The LDN Research Trust, European LDN Conference 2009, Glasgow.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Linda has had MS for 20 yrs. Has been on LDN 5.5 yrs.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; "&gt;Today she appears totally symptom free.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; min-height: 14px; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Before LDN she has very limited mobility, cognitive issues in communicating and severe muscular problems.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;In December 2003 she started taking LDN&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;She saw a dramatic improvement in 3 weeks - fatigue, sight, bladder - all improved.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Subsequently Linda set-up The LDN Research Trust (LDNRC) as a charity.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;All work is voluntary work, just the running costs are paid from donations.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;So far they have raised £22K towards a clinical trial in the UK.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;LDNRC's aim - Get LDN on the UK NHS for everyone.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;There are 4200+ registered LDN users with the LDNRC.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;3000 are in the UK&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;90% have MS, others have Crohn's, ME, Parkinson's, Cancer and various other conditions.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Citizens of the US and other countries are welcome to register&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Linda's current condition - She finds that getting an infection or virus brings on her MS symptoms (NOTE - Some people say they don't get infections or viruses at all while on LDN). But she finds the symptoms subside once the infection or virus is gone.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Linda thanked the following two individuals in particular for her recovery with LDN -&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Dr Bob Lawrence - Who introduced LDN to UK&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Dr Tom Gilhooly - For his efforts to bring about a clinical trial in the UK.&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;Further reading :&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;a href="http://ldnresearchtrust.org"&gt;http://ldnresearchtrust.org&lt;/a&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;a href="http://ldnnow.co.uk"&gt;http://ldnnow.co.uk&lt;/a&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;br /&gt;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; margin-left: 0px; padding-top: 0px; padding-right: 0px; padding-bottom: 0px; padding-left: 0px; border-top-width: 0px; border-right-width: 0px; border-bottom-width: 0px; border-left-width: 0px; border-style: initial; border-color: initial; outline-width: 0px; outline-style: initial; outline-color: initial; font-size: 12px; vertical-align: baseline; background-image: initial; background-repeat: initial; background-attachment: initial; -webkit-background-clip: initial; -webkit-background-origin: initial; background-color: transparent; font: normal normal normal 12px/normal Helvetica; "&gt;&lt;a href="http://essentialhealthclinc.com" style="text-decoration: none;"&gt;http://essentialhealthclinc.com&lt;/a&gt;&lt;/p&gt;&lt;/div&gt;&lt;/span&gt;&lt;/div&gt;&lt;/span&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-1787756218509608688?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/1787756218509608688/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ldn-personal-experience-linda-elsegood.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1787756218509608688'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/1787756218509608688'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/ldn-personal-experience-linda-elsegood.html' title='LDN A Personal Experience - Linda Elsegood of The LDN Research Trust, European LDN Conference 2009, Glasgow.'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-8882220068057629879.post-7570082740639583908</id><published>2009-04-26T08:20:00.000-07:00</published><updated>2009-04-26T10:27:49.863-07:00</updated><title type='text'>Low Dose Naltrexone (LDN) on the NHS</title><content type='html'>&lt;div&gt;&lt;span class="Apple-style-span" style="font-family: 'Lucida Grande'; white-space: pre; "&gt;&lt;b&gt;&lt;span class="Apple-style-span" style="font-size: large;"&gt;Low Dose Naltrexone (LDN) on the NHS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;Surprisingly enough, this blog is aimed at helping to get &lt;a href="http://lowdosenaltrexone.org/"&gt;Low Dose Naltrexone&lt;/a&gt; (LDN) available via prescription in the United Kingdom's National Health Service (NHS).&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;&lt;a href="http://en.wikipedia.org/wiki/Low_dose_naltrexone"&gt;wikipedia&lt;/a&gt; has a short page on LDN (Surprisingly un-informative, the lowdosenaltrexone.org link above is more useful).&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;The &lt;a href="http://www.ldnresearchtrust.org/"&gt;LDN Research Trust&lt;/a&gt; is a UK charity which aims to increase awareness of LDN and it's uses and to raise funds for clinical trials to provide evidence of it's efficacy in treating auto-immune diseases and other conditions.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;Dr Tom Gilhooly and his partner pharmacy, Dicksons's has been instrumental in publicising LDN in Scotland the UK generally via his &lt;a href="http://essentialhealthclinic.com/"&gt;clinic&lt;/a&gt; in Rutherglen, Glasgow. &lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;Dr Gilhooly organised an EU conference on LDN in &lt;a href="http://glasgowldn2009.com/"&gt;Glasgow&lt;/a&gt; which has just been held.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;The next one will also be held in Glasgow in 2010, and will be over 2 days, 1 for clinicians and researchers and one open the public also.&lt;/div&gt;&lt;div&gt;&lt;br /&gt;&lt;/div&gt;&lt;div&gt;I attended this conference and will be providing some notes on the content of the presentations given at it in this blog in subsequent postings.&lt;/div&gt;&lt;div class="blogger-post-footer"&gt;&lt;img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/8882220068057629879-7570082740639583908?l=ldnonthenhs.blogspot.com' alt='' /&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://ldnonthenhs.blogspot.com/feeds/7570082740639583908/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/low-dose-naltrexone-ldn-on-nhs.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7570082740639583908'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/8882220068057629879/posts/default/7570082740639583908'/><link rel='alternate' type='text/html' href='http://ldnonthenhs.blogspot.com/2009/04/low-dose-naltrexone-ldn-on-nhs.html' title='Low Dose Naltrexone (LDN) on the NHS'/><author><name>Bob</name><uri>http://www.blogger.com/profile/06078471392658660581</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='http://img2.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry></feed>
